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Abstract 
 Biofilms are highly complex bacterial aggregates, surrounded by extracellular 
polymeric substances (EPS). Each matrix component has specific functions contributing to the 
maintenance of the biofilm health. In the EPS matrix, extracellular deoxyribonucleic acid 
(eDNA) is present at the bacterial cell surface and plays an essential role in several stages of 
biofilm formation, namely it determines biofilm architecture, provides mechanical stability to 
biofilms, protects bacterial cells in biofilms from physical stress, antibiotics and detergents and 
could be a significant source of organic nutrients in the environment whilst disseminating 
genes amongst different microorganisms. In this context, attacking this essential component of 
the EPS matrix by deoxyribonuclease I (DNase I), an endonuclease that digests DNA through 
hydrolysis of the phosphodiester bonds, has been considered a possible approach to prevent 
biofilm formation. 
In this work, covering titanium, a common orthopaedic implant material, with a 
protective biodegradable poly(lactic-co-glycolic acid) (PLGA) coating containing embedded 
DNase I, has been found to be a promising strategy to prevent the initial bacterial adhesion 
and biofilm formation in vitro. Employing coatings of PLGA-DNase I and PLGA-inulin packaged 
DNase I, bacterial adhesion and biovolumes of biofilms of up to 120 h old, of both 
Staphylococcus aureus ATTCC 12600GFP or Staphylococcus aureus Newman D2CGFP, decreased 
substantially with respect to uncoated titanium. It is expected that a timescale of 120 h is 
sufficiently long to prevent infection arising from peri-operatively introduced bacteria as is 
currently done with a dose of post-operatively administered antibiotics. Without the risk of 
bacterial resistance development, the PLGA-inulin packaged DNase I coating provides an 
appropriate and effective strategy to prevent biofilm formation on the surface of biomaterial 
implants and devices. In addition, the contact between U2-OS cells and the developed PLGA 
coatings does not negatively affect their viability and proliferative capacity, as well as the 
adhesion to the surface of the coatings. Therefore, this approach should be further explored to 
determine whether it can mitigate the occurrence of biomaterial-associated infections (BAI) in 
vivo, which are responsible for several clinical complications and high healthcare costs. 
   
Keywords: Biomaterial-associated infections (BAI); eDNA; anti-biofilm strategies; DNase I; 
poly(lactic-co-glycolic acid) (PLGA).  
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Resumo 
Os biofilmes são agregados bacterianos altamente complexos, rodeados por 
substâncias extracelulares poliméricas (EPS). Na matriz da EPS, o ácido desoxirribonucleico 
extracelular (eDNA) está presente na superfície das células bacterianas e desempenha um 
papel essencial em várias fases da formação do biofilme, nomeadamente determina a sua 
arquitetura, proporciona estabilidade mecânica, protege as células bacterianas de stress físico, 
antibióticos e detergentes, e pode ser uma fonte significativa de nutrientes orgânicos no 
ambiente enquanto dissemina genes entre diferentes microrganismos. Neste contexto, atacar 
este componente essencial da matriz de EPS utilizando desoxirribonuclease I (DNase I), uma 
endonuclease que digere DNA por hidrólise das ligações fosfodiéster, tem sido considerada 
uma possível abordagem para evitar a formação de biofilmes. 
No presente trabalho, o revestimento de titânio, material comummente utilizado em 
implantes ortopédicos, com uma proteção biodegradável de poli(ácido láctico-co-ácido 
glicólico) (PLGA) incorporando DNase I, mostrou ser uma estratégia promissora para prevenir 
a adesão bacteriana inicial e a formação de biofilmes in vitro. Comparativamente à superfície 
de titânio não revestida, os revestimentos PLGA-DNase I e PLGA-inulina incorporando DNase I 
diminuíram significativamente a adesão bacteriana e os biovolumes dos biofilmes constituídos 
por Staphylococcus aureus ATTCC 12600GFP ou Staphylococcus aureus Newman D2CGFP com 
24 h, 72 h e 120 h de crescimento. É expectável que 120 h seja um período de tempo 
suficientemente longo para evitar a ocorrência de infecções resultantes da entrada de 
bactérias no período peri-operatório. Sem apresentar risco de desenvolvimento de resistência 
bacteriana, o revestimento PLGA-inulina incorporando DNase I constitui uma estratégia 
adequada e eficaz para prevenir a formação de biofilmes na superfície de implantes de 
biomateriais e dispositivos. Adicionalmente, o contacto entre as células U2-OS e os 
revestimentos de PLGA desenvolvidos não afecta negativamente a sua viabilidade e 
capacidade proliferativa, assim como a sua adesão à superfície dos revestimentos. Portanto, 
esta abordagem deve ser explorada no futuro de forma a concluir se pode mitigar in vivo a 
ocorrência de infecções associadas aos biomateriais (BAI) responsáveis por várias 
complicações clínicas e altos custos de saúde. 
 
Palavras-chave: Infeções associadas aos biomateriais (BAI); eDNA; estratégias anti-biofilme; 
DNase; revestimentos de poli(ácido láctico-co-ácido glicólico) (PLGA).  
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1.1. Contextualization and aims 
Currently, the average prevalence of healthcare-associated infections (HAI) in Europe is 
7.1%, resulting in costs exceeding € 7 billion annually [1]. An interesting aspect is that hospital 
acquired infections increased, even though the average length of hospitalization has decreased 
[2]. The major proportion of HAI consist of biomaterials-associated infections (BAI) [3], which is 
due to the increased use of biomaterials and biomedical devices (as the presence of a foreign 
body considerably reduces the number of bacteria required to produce an infection [2]), 
caused by an aging population and improved materials technologies development [4,5]. BAI is 
the number one cause of failure of biomaterial implants or devices [6,7] and usually results 
from the presence of biofilms [3].  
The microorganisms most frequently associated with BAI are staphylococci [8]. Their 
capability to adhere to materials and to promote the formation of biofilms is the key feature of 
their pathogenicity [9]. Therefore, this study involves two Staphylococcus aureus strains, ATCC 
12600 (common reference strain in biofilm research) and Newman D2C (extremely virulent 
clinical isolate, known to cause persistent infections) [10].  
Biomedical engineers are involved not only in the creation and construction of 
biomaterials and biomedical devices, aimed to significantly contribute to improving quality of 
life, but also in the development of strategies to prevent the occurrence of problems during 
their use. In this context, it is also in part their responsibility to seek ways of preventing BAI. 
This objective can be achieved by the use of materials, as well as the development of coatings, 
which are less susceptible to colonization by pathogenic microorganisms [11]. 
This thesis focusses on the implementation of an enzymatic coating aiming to prevent 
bacterial adhesion and biofilm formation on titanium surfaces (titanium is a commonly used 
orthopaedic biomaterial) [12]. More specifically, the ultimate goal is to avoid the occurrence of 
BAI using biodegradable coatings of poly-(lactic-co-glycolic acid) (PLGA) incorporating 
deoxyribonuclease (DNase) I subjected to inulin packaging. In order to achieve this goal, the 
release kinetics of DNase I from both protective PLGA coatings with DNase I and inulin 
packaged DNase I were determined, the “initial burst” of DNase I released from the PLGA 
coatings was mitigated or eliminated, an in vitro model for the assessment of biofilm formation 
over prolonged periods of time (120 h) was developed, and finally, it was determined whether 
the approach developed increases bacterial susceptibility to gentamicin.  
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1.2. Biomaterial-Associated Infections 
1.2.1. Biofilms on medical devices 
Embedded in a biopolymeric matrix, infectious biofilms can be categorized into tissue-
associated or mucus-embedded cellular aggregates, for instance, in chronic wounds or in the 
lumen of the bronchi in patients with cystic fibrosis, and surface-related, when attached to the 
surface of devices such as implants or catheters (Figure 1.1) [13].  
 
 
Figure 1.1. Schematic representation of the bacterial biofilms development from planktonic bacteria. The 
pathway on the top describes the development of non-surface-attached biofilms (host materials embedded). 
The pathway below shows the surface-attached biofilms. Adapted from [13]. 
 
During the past decades there has been an increase in the use of biomaterials and 
biomedical devices (both used for restoration or support of human functions) due to an aging 
population and to improved materials technologies (including biocompatibility, functionality, 
and durability). However, the application of these devices can lead to BAI, usually resulting 
from the presence of biofilms [4,5]. Biofilms are abundant in nature [3] and it is estimated that 
80% of human infections are related to biofilm formation [4]. The presence of an implanted 
material alone increases the risk of infection dramatically and it has been demonstrated that 
104 times fewer bacteria are necessary to infect human volunteers receiving a suture 
compared to those suture-free [14]. Biofilm formation has been demonstrated for numerous 
pathogens associated with chronic infections and it is evidently an essential microbial survival 
strategy [8,15]. In that aspect, biofilm growth can be considered as a virulence factor, even 
though perhaps not completely correct as by definition, it does represent a bacterial tactic that 
contributes to its capability to cause an infection [8].  
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The first step of biofilm formation on an indwelling medical device is the surface 
conditioning by a layer of organic material (the constitution of this layer depends on the 
anatomical place of utilization of the medical device, although many of the molecules are 
proteinaceous and influence bacterial adhesion), which is deposited on the surface as a 
consequence of the contact between the material and body fluids [16-18]. This step influences 
all the following phases of biofilm formation (initial attachment, irreversible attachment, early 
development of biofilm architecture, maturation and dispersion – detailed in section 1.3.2), 
since the bond formed between the proteinaceous film and the bacteria represents the link to 
the growing biofilm [7,17,18]. When settled, the developed biofilm on the biomaterial surface 
shares the fundamental features of all bacterial biofilms [16].  
It is of crucial relevance for the first steps of biofilm formation whether microbial 
contamination of the biomaterial surface occurs in a dry state, by mechanical transfer directly 
from contaminated objects and by airborne bacteria, or in wet conditions, from the contact 
with artificial aqueous solutions or physiological fluids. In the first two cases of contamination, 
the deposition of bacteria can be avoided by adequate sterility of the operating room and 
rigorous aseptic procedures during manipulation of sterile devices and surgery. On the other 
hand, the procedures to eradicate the microbial contamination resulting from the contact with 
liquid carriers (like blood, serum, saliva, eye aqueous humour and urine) are more complex, 
since in aqueous solutions bacterial adhesion on biomaterial surfaces is affected by numerous 
variables such as surface morphometry, physico-chemical properties, environmental conditions 
and the type of pathogen (Table 1.1) [18].  
 
Table 1.1. Variables affecting the bacterial adhesion and colonization onto biomaterial surfaces. Taken from 
[18] 
Variables controlling bacterial adhesion and colonization 
Surface morphometry Macroporosity, microporosity, micro-roughness, nano-roughness 
Physico-chemical properties Surface energy, hydrophylicity/superhydrophylicity, hydrophobicity/ 
superhydrophobicity, hydrophobic functional group, polar functional groups, 
charged functional groups, functional groups with specific activities, degree 
of hydration 
Environmental conditions Electrolytes, pH, temperature, host proteins/host adhesins, shear rate/fluid 
viscosity, fluid flow rate 
Pathogen Gram-positive/Gram-negative, genus/species, bacterial shape, surface 
energy, strain type and specific set of expressed adhesins 
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1.2.2. Microorganisms commonly associated with medical 
devices 
A diversity of microorganisms has been unambiguously associated with BAI. Various 
microorganisms, including several species of bacteria and fungi [4], share a common ability to 
form biofilms and colonize human tissues in the presence of foreign bodies [17]. However, BAI 
is typically caused by commensal bacteria [19].  
The microorganisms that are most frequently associated with orthopaedic medical 
devices are staphylococci (particularly Staphylococcus epidermidis and S. aureus), followed by 
Pseudomonas aeruginosa and other environmental bacteria (Figure 1.2) that opportunistically 
infect an immunologically susceptible host [8]. Other bacterial genera and staphylococcal 
species are emerging as new pathogens such as Enterococcus faecalis (a strong biofilm 
producer showing many virulence factors and differently resisting antibiotics) and 
Staphylococcus lugdunensis (a producer of mainly proteinaceous biofilms) [18]. 
 
 
Figure 1.2. Frequency of the main pathogenic species found among orthopaedic clinical isolates of implant-
associated infections. Adapted from [20]. 
 
Despite the development of several strategies to control BAI, few biomaterials have 
been designed that effectively reduce the incidence of BAI [6,7]. Implanted medical devices are 
especially susceptible to microbial biofilm formation, since these surfaces are not well 
protected by host defences, thus offering sites to which the pathogens have access [17]. 
Biofilm growth occurs even in permanent, completely internal implants and devices particularly 
developed to selectively favor host tissue integration over bacterial adhesion, since numerous 
microorganisms use equivalent adhesive mechanisms as host tissue cells [6].  
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According to Busscher et al. [6], all biomaterial implants and devices can be affected 
by microbial contamination and clinical infection. Thus, numerous indwelling medical devices 
are colonized by biofilms, resulting in measurable rates of BAI (Table 1.2) [3].  
 
Table 1.2. Incidence and major causative agents of infections associated with commonly used medical 
devices and implants. Adapted from [4] 
Implants or devices Major causative organisms Incidence 
Urinary catheter Escherichia coli, candida spp., coagulase negative 
staphylococci (CoNS), E. faecalis, Proteus mirabilis 
33 % 
Central venous catheter CoNS, S. aureus, Enterococcus spp., Candida spp., Klebsiella 
pneumoniae 
2 – 10 % 
Peritoneal catheter S. aureus, P. aeruginosa, Candida spp. 3 – 5 % 
Mechanical heart valve CoNS, S. aureus, Streptococcus spp., Enterococcus spp. 1 – 4 % 
Ventricular assist device CoNS, S. aureus, Candida spp., P. aeruginosa 13 – 80 % 
Coronary stents S. aureus, CoNS, P. aeruginosa, Candida spp. < 0.1 % 
Cardiac pacemakers S. aureus, CoNS, Streptococcus spp., Candida spp. 0.1 % - 20 % 
Vascular grafts S. aureus, S. epidermidis, Pseudomonas spp., Enterococcus 
spp., Enterobacter spp. 
1 % – 6 % 
Contact lenses P. aeruginosa, Serratia marcescens, S. aureus 0.1 % 
Intraocular lenses S. epidermidis 0.1 % – 0.5 % 
Fracture fixation devices CoNS, S. aureus, Propionibacterium spp., Streptococcus spp., 
Corynebacterium spp. 
5 % 
Hip/knee implants S. aureus, CoNS, Streptococcus spp., Enterobacteriaceae 0.5 % – 4 % 
Dental implants Streptococcus spp., Actinomyces spp., Porphyromonas spp., 
Prevotella spp. 
5 % – 8 % 
Penile implants CoNS, Staphylococcus spp., Enterobacter spp., Pseudomonas 
spp. 
2 % – 5 % 
Pelvic organ prolapse 
mesh 
CoNS, Streptococcus spp., Enterobacter spp., Pseudomonas 
spp. 
0 – 8 % 
Cochlear implants S. aureus, P. aeruginosa, Haemophilus influenza, 
Streptococcus spp. 
1.4 % – 17 % 
Sutures S. aureus, S. epidermidis, CoNS, Peptostreptococcus spp., 
Bacteroides fragilis, E. coli, Enterococcus spp., P. aeruginosa, 
Serratia spp. 
Unknown 
Breast implants S. aureus, CoNS, Streptococcus, Propionibacterium spp. 1 % – 2. 5 % 
Intrauterine device  Candida albicans, CoNS [3] Unknown 
Artificial voice prosthesis  C. albicans, CoNS [3] Unknown 
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Staphylococci are responsible for an increasing number of infections in joint 
prostheses, immunosuppressants and catheters [21]. Nowadays, S. epidermidis and S. aureus 
together account for about 65% of prosthetic joint infections (PJIs). These two species are the 
most commonly reported microorganisms both in early and late infections in total knee and hip 
arthroplasty [22]. It is important to emphasize that, although in the last five decades technical 
and operational measures to reduce the risk of infection in the use of prosthetic joints have 
been implemented, the increasing number of joint replacements makes the absolute number 
of such infections remain significant, representing substantial costs to healthcare systems 
around the world (Figure 1.3) [23]. 
 
 
Figure 1.3. Projections of the worldwide increase of arthroplasties from 2005 to 2030. Taken from [24]. 
 
It seems impossible to develop biomaterial surfaces capable of preventing bacterial 
adhesion regardless of the aetiological agent and the physiological environment. Nonetheless, 
the knowledge of the most prevalent pathogens causing BAI and of their respective 
characteristics can be studied in order to lower the chance of bacterial colonization on the 
developed surfaces [18]. 
Members of the genus Staphylococcus belong to the family Micrococcaceae and have 
a Gram-positive cell wall structure. Staphylococci are characterized by round shaped cells and, 
similarly to all medically important cocci, they are non-flagellate, non-motile and non-spore 
forming. These cells tend to be arranged in grape-like clusters (microscopically the best known 
aspect of these bacteria after gram-staining) (Figure 1.4), although some single cells, pairs and 
short chains are also seen. Staphylococcus spp. grow either by anaerobic respiration 
(preferentially) or by fermentation that produces mostly lactic acid [25-28].  
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Figure 1.4. A false-color scanning electron micrograph of S. aureus illustrating the typical grape-like cluster 
of cocci. Scale bar represents 1 µm. Adapted from [29]. 
 
Staphylococcus spp. can be allocated in two groups based on the ability to produce 
the enzyme coagulase: coagulase-positive (mainly represented by S. aureus) and CoNS (which 
includes S. epidermidis) [26]. CoNS are generally less virulent [30].  
The most notable characteristic of the adherent staphylococci colonizing medical 
implants is the abundant amount of EPS that encloses and protects cells from host defences 
and antibiotic treatment [8,31]. This defense mechanism makes staphylococcal biofilms that 
form on tissues or medical devices extremely difficult to eradicate [31]. The biofilm formation 
of S. aureus is a complicated process impacted by multiple factors such as extracellular DNA 
(eDNA) (the main structural component in the biofilm matrix), surface-associated proteins, cell 
wall teichoic acids, and an intercellular polysaccharide adhesin (PIA) (also named poly-N-acetyl-
glucosamine (PNAG)) (Figure 1.5) [18,31-33]. The glycocalix of the majority of biofilm-
producing staphylococcal strains contains PIA [18], produced by the ica operon (although not 
all strains carry this operon) [31,34], and constituted of b-1,6-linked N-acetylglucosamine 
residues and an anionic portion with a lower content of non-N-acetylated D-glucosaminyl 
residues [35]. The increasing incidence of methicillin-resistant S. aureus (MRSA) has 
intensified efforts to discover different ways to fight these pathogens [10,31].  
 
 
Figure 1.5. The major biofilm exopolysaccharide of staphylococci is intercellular polysaccharide adhesin 
(PIA) (blue: deacetylation creates free amino groups that at neutral or acid pH give the molecule a cationic 
character). Adapted from [36]. 
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1.2.3. Risk factors underlying the development of BAI 
BAI may result in clinical complications, including death. Furthermore, BAI also 
increases healthcare costs caused by prolonged hospital stays and revision surgeries [4].  
Focusing on the possibility of infections, the implant surgery can be considered a 
success when no complications for the patient arise, in the short and in the long term, or a 
failure, in the case of infection. In the latter case, contamination can occur in the perioperative 
or early postoperative stage, when microorganisms enter the wound or adhere to the implant 
during surgery, or in the late postoperative stage, when microorganisms infect the patient 
during hospitalization, or even afterwards (Figure 1.6) [4,6,37,38]. Generally, peri-/early 
postoperative infections are detected within a short period of time after surgery (but also can 
cause BAI many years after implantation, since bacteria can stay inactive on an implant 
surface for several years inside the human body or in adjacent tissue [37,38]), whereas the 
late postoperative infections represent more serious consequences for the patient and are 
considerably more difficult to detect and treat, since they derive from the hematogenous 
spreading of bacteria through blood from infections elsewhere in the human body. In such 
circumstances, the effective protection is only obtainable by integration of the biomaterial into 
host tissues and establishment of a normal host immune response at the implant site [6]. 
 
 
Figure 1.6. Patient-associated risk factors underlying the development of BAI. Revision surgery patients are 
at greater risk than primary surgery implant patients. The risk of an implant or device becoming infected 
hematogenously decreases with time after implant placement due to more extensive host tissue integration. 
Taken from [6]. 
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Typically, biofilms are found in chronic diseases that resist host immune responses 
and antibiotic treatment [5,15]. Nonetheless, in BAI, no chronic disease is needed for biofilm 
formation [5]. Although acute (planktonic) infection generally requires only one single 
antimicrobial treatment to eliminate microorganisms, chronic (biofilm) infections may need 
sophisticated diagnostic procedures, long-term antimicrobial therapy and repetitive surgical 
interventions [19]. Biofilms present several characteristics that can be essential in the 
development of infections, such as adherent bacteria escaping routine diagnostic methods, 
infection persistence despite susceptibility of planktonic bacteria to the antimicrobial agent, 
and host defenses being unable to eradicate microorganisms, i.e. natural healing does not 
occur [3,5]. When an infection of an indwelling or implanted foreign body is suspected, a 
general decision has to be addressed; whether to remove the foreign body or to initiate 
calculated antimicrobial treatment [9]. 
Several medical interventions are currently used to treat BAI, including long-term 
antimicrobial strategies and combinations of antibiotics (treatment with antibiotics slows down 
biofilm progression by eliminating planktonic cells and interfering with biofilm metabolism) 
[39]. BAI is typically treated with vancomycin (frequently in combination with rifampicin) and in 
some cases eventually by surgical revision. Unfortunately, these interventions carry the risk of 
re-infection, often at a higher rate, and the development of antibiotic resistance due to changes 
in bacterial resistance patterns (vancomycin treatment has a reasonably high failure rate, 
which may compromise the result of revision surgery) [4,6,19]. Bacteria infecting a secondary 
implant may arise from peri-implant tissue and usually have been exposed for longer periods of 
time to antibiotics, possibly creating resistance or altering their adhesiveness for a new implant 
surface. Accordingly, after the occurrence of infections, the placement of secondary implants 
and devices require different methodologies to eliminate bacteria, because improper removal 
increases the chance of recurring infections [6,19].  
It is essential to reduce the number of BAI since biofilms cause persistent infections 
and often the removal of the colonized implant or device is the only successful treatment 
option [12]. Moreover, future research should also try to develop strategies to prevent 
infections of secondary implants after BAI of a primary implant, due to the high incidence rate 
at which these infections occur [19]. According to Zimmerli et al., the prerequisite for correct 
treatment of BAI is a balanced concept of the optimal surgical and antimicrobial therapy [5]. 
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1.3. Biofilms 
1.3.1. Biofilm formation and development 
In natural environments, medical and engineered systems [40], bacteria are 
predominantly organized in structured communities so-called biofilms [41], the primary mode 
of microbial existence [16]. In fact, bacterial cells prefer to adhere, aggregate, colonize 
materials and grow into a mature biofilm, rather than staying planktonic [42]. 
Biofilms are surface-associated complexes constituted by numerous microorganisms 
(single or multiple species) exhibiting an altered phenotype compared to planktonic cells and 
are encased in a self-produced extracellular matrix [39,41,43,44]. In nature, biofilms can form 
a single layer or a 3-Dimensional (3-D) structure and are able to present a high level of 
organization [45], by working as a cooperative conglomerate [40]. 
Biofilm formation and development occurs on almost all surfaces [46] and is affected 
by many parameters related to the properties of the substratum, surrounding fluid and the cell 
type (Table 1.3) [25,47]. 
 
Table 1.3. Variables important in cell attachment and biofilm formation. Adapted from [25] 
Properties of substratum Properties of surrounding fluid Properties of the cell 
Texture or roughness Flow velocity Cell surface hydrophobicity 
Hydrophobicity pH Fimbriae 
Conditioning film Temperature Flagella 
 Cations Adhesion molecules 
 
There are several reasons why the biofilm lifestyle is advantageous compared to 
planktonic life. Biofilms act as a barrier that prevents or reduces the contact with 
antimicrobials agents [47] by causing poor penetration of these agents through the surface film 
that covers the microbial community and also because of inactivation of the antimicrobials by 
the extracellular matrix [46]. For this reason, biofilms contribute to the protection of individual 
bacteria, providing them resistance against antibiotics, biocides or predators [41,43]. Biofilms 
also facilitate acquisition of nutrients and promote genetic exchange [43]. Inside the biofilm the 
chemical composition is highly dynamic, encouraging solute gradient formation and nutrient 
exchange [41], whereas a high local density provides a stable structured environment for 
genetic exchange events [43]. 
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1.3.2. The life cycle of a biofilm 
The identification of novel targets to prevent and control the formation of biofilms (for 
applications in both industry and medicine) is one of the main motivations for current efforts in 
trying to clearly understand the life cycle of biofilms [40].  
The biofilm life cycle is highly dynamic and consists of predictable transitions (initial 
attachment, irreversible attachment, early development of biofilm architecture, maturation and 
dispersion) from single cells to complex microcolonies, the basic organizational units of a 
biofilm (Figure 1.7) [39,40,47].  
 
 
Figure 1.7. Sequential steps of biofilms development. From right to left: initial attachment, irreversible 
attachment, early development of biofilm architecture, maturation and dispersion. Taken from [40]. 
 
In the bacteria’s initial attachment, an equilibrium between adhering and suspended 
cells exists. The adherent cells have a small quantity of extracellular polymeric substances 
(EPS) and many are able of autonomous movement. In this stage, adhesion is reversible (the 
bacteria are poorly connected to the surface) as the attached cells are not yet pledged to the 
differentiation process that leads to biofilm formation [39,47]. As mentioned, frequently, the 
first step comprises surface conditioning, characterized by the formation or accumulation of an 
organic layer responsible for neutralizing the excess charge and free energy of the surface, in 
order to permit adhesion [39,48]. 
In irreversible attachment, permanent bonding between the bacterial cells and the 
surface occurs in the presence of EPS [47] which is produced due to stimulation of membrane-
bound sensory proteins of the cells. Subsequently, the development of cell-to-cell bridges 
cements the cells to the surface [39]. 
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The simultaneous accumulation and growth of microorganisms results in microcolony 
formation. During this phase, recruitment and entrapment of planktonic cells from the adjacent 
medium takes place as a result of cell-to-cell communication, also referred to as quorum 
sensing [48]. Microcolonies are advantageous because they provide interspecies exchange and 
mutual end-product removal [39,47]. 
Biofilm maturation corresponds to the development into an organized and complex 
structure (the biofilm shape depends on the stress to which it is exposed and the source of 
nutrients [48]). At this stage, attached bacteria grow and divide under sessile conditions into 
mixed complex-enclosed microcolonies dispersed with highly permeable water channels 
carrying nutrients and waste products [39,47]. These channels form the primitive circulatory 
system for maintaining homeostasis inside the biofilm [48]. 
Finally, the dispersion (also known as detachment or dissolution) from the mature 
biofilm is a process [39] that allows the cells (differentiated and highly motile cells [40]) to 
revert into their planktonic form. The cells are able to migrate to new surfaces, attach and 
mature into new 3-D communities, including microcolonies [40]. Several strategies have been 
suggested regarding how biofilm bacteria disseminate into other areas for further surface 
colonization [39]. In the case of active dispersal, the production of specific dispersal cells is an 
active and highly regulated response. On the other hand, in the passive dispersal, the 
scattering is the result of cell release and erosion from the biofilm [40]. There are several 
causes of biofilm detachment such as external perturbation, internal biofilm processes and 
starvation [47,48]. Dispersal becomes especially important when deterioration of the local 
habitat quality inside the biofilm occurs [41]. In that sense, this phase is considered crucial for 
the preservation of biofilm sustainability [49]. Ideally, bacteria should adjust their behavior 
according to the current environmental context, depending on the ability to recognize and reply 
to environmental signals in a timely manner [41]. 
Despite the vast amount of information about biofilms, there is still a great lack of 
detailed knowledge regarding crucial steps in the formation of biofilms, such as biofilm 
structuring, detachment and the production of persistent cells (a small subpopulation of 
dormant cells that are multi-drug tolerant and resist to antibiotic treatment [13,50]) [48,49]. 
This type of cells are partly responsible for antibiotics resistance and, consequently, their 
understanding is essential for directing further research towards the development of effective 
strategies against biofilm development [48]. 
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1.3.3. Biofilm structure: Extracellular polymeric substances 
matrix 
1.3.3.1. Definition, composition and spatial distribution 
Biofilms are largely comprised of microbial cells and EPS (50% to 90% of the total 
organic carbon of biofilms), which is present both outside of the cells and in the interior of 
microbial aggregates [51]. Some commonly found constituents of EPS are water (biofilms are 
extremely hydrated, with fluid-filled channel running throughout the biofilm), 
exopolysaccharides [48], proteins, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) 
(Table 1.4) [25].   
 
Table 1.4. Components of biofilms. Adapted from [25] 
Component Percentage of matrix 
Water > 97 % 
Microbial cells 2 % - 5 % (many species) 
Exopolysaccharides 1 % - 2 % 
Proteins < 1% - 2 % 
DNA and RNA < 1 % - 2 % 
 
There is no biofilm without an EPS matrix, [32] which usually consists of a complex 
mixture of exopolysaccharides, proteins, eDNA, amyloid fibres, bacteriophages and other 
macromolecules (Figure 1.8). The EPS also incorporates large amounts of water [3,40,41,52]. 
The nature of EPS depends on the growth conditions, medium and substrates [34]. EPS is 
essentially the result of high-molecular-weight secretions from microorganisms and the 
products of cellular lysis and hydrolysis of macromolecules, although some organic matters 
from wastewater can also be adsorbed onto the EPS matrix [51]. 
According to several studies, the distribution of various EPS components is 
heterogeneous and depends on the microbial aggregate type, structure and origin [51]. In fact, 
the EPS of biofilms is generally not uniform but may vary spatially and temporally. Additionally, 
different organisms produce differing amounts of EPS and those amounts increase with the 
biofilm aging [3]. The spatial distribution of EPS is usually studied using confocal laser 
scanning microscopy (CLSM) or fluorescent microscopy (after EPS is stained by fluorescent 
dyes or lectins) [51]. 
Introduction 
16 | Chapter 1 
 
 
Figure 1.8. The complex structure of bacterial biofilms. Microcolonies in the mature biofilm are 
characterized by an EPS matrix typically constituted by exopolysaccharides, proteins, eDNA, amyloid fibres, 
bacteriophages and other macromolecules. Adapted from [40]. 
 
1.3.3.2. Functionality 
The uniqueness of the matrix constituents, the chemical diversity and adaptability of 
the EPS matrix are significant factors that assist the different bacterial species and strains to 
ensure the satisfaction of their own particular needs [53]. Each matrix component has specific 
functions (not all are exactly known) contributing to the maintenance of the biofilm health [12]. 
Some of the most important functions of the EPS matrix are related to the stabilization 
of the biofilm structure, protection of the bacterial community, nutrients gathering and 
facilitation of the exchange of genetic information. In addition, the EPS matrix also creates 
gradients within the biofilm, for instance oxygen and nutrients dispersing inwards, and waste 
products, as well as signals such as nitric oxide diffusing outwards (Figure 1.8) [40,52,54]. 
Briefly, the EPS matrix offers the scaffold for adhesion to a surface and cohesion between cells 
[54]. The EPS matrix also works as a shield offering resistance against predators and chemical 
toxins [3,39,40]. The EPS matrix can impede the access of some components of the host 
immune system, such as macrophages, which display partial penetration into the matrix and 
“frustrated phagocytosis”. The matrix retains nutrients and several biologically active 
molecules (such as cell communication signals) in order to immobilize the bacteria. In 
addition, the EPS matrix may simulate an external digestion system, collecting valuable 
enzymes that can degrade various matrix constituents, as well as any nutrients or other 
substrates (after the degradation, the products are close to the cells, facilitating uptake), and 
also promotes the recycling of lysed cell components [40,54]. 
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1.3.3.3. Extracellular DNA 
1.3.3.3.1. Origin 
When a cell dies, the genetic coding material or DNA contained within the cell can 
sometimes survive intact in a protected environment for many years [55]. When the bacterial 
DNA is not contained within the cell anymore, it is referred to as eDNA. This eDNA is present 
on the bacterial cell surfaces, becoming an integral part of the matrix and of the biofilm mode 
of life and it is not different from chromosomal DNA [32,46,55]. 
The amount and localization of eDNA in biofilms varies considerably among different 
species and may be very different even between related species [32]. In addition, eDNA 
concentration in biofilms differs substantially over time during the biofilm development [56]. In 
some cases, it is the most abundant matrix polymer in the biofilm [54]. Studies have shown 
that eDNA accumulates in the late exponential growth phase of planktonic batch cultures [56].  
The mechanism of eDNA production seems to differ between species [32] and is still 
under debate [46], but it is believed that eDNA is released due to various mechanisms such as 
controlled lysis of subpopulations of bacterial cells (considered the main origin of eDNA in the 
mature biofilm matrix [54]) prompted by prophages, enzymes, lytic proteins and metabolites or 
by physical and chemical approaches, but also via active release by bacterial membrane 
vesicles [57]. However, it should be noted that the source of eDNA in a biofilm matrix may 
even be partly human (as happens for biofilms isolated from the lungs of cystic fibrosis 
patients) [54].  
 
1.3.3.3.2. Role 
Biofilm development is profoundly influenced by the presence of several chemical 
structures on bacterial cell surfaces [57].  
These days, the importance of eDNA in biofilm formation is unquestionable [54], 
however, initially, eDNA was assumed as a product with no functions besides carrying genetic 
information [56]. Present at the bacterial cell surface [58], eDNA plays an essential role in 
several stages of biofilm formation, determines biofilm architecture [46], provides mechanical 
stability to biofilms, protects bacterial cells in biofilms from physical stress, antibiotics and 
detergents [34,57,59] and could be a significant source of organic nutrients in the 
environment whilst disseminating genes amongst different microorganisms [55].  
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The role of eDNA in biofilm formation has mostly been studied in clinically important 
strains [56]. The development and stability of S. aureus biofilms relies on eDNA secretion. For 
example, in order to cause dispersion of the biofilm, S. aureus produces enzymes that degrade 
the eDNA [40]. In addition, during biofilm formation, the removal of eDNA or blocking of eDNA 
production causes a decrease in S. aureus adhesion. The removal of eDNA also affects the 
initial adhesion of S. epidermidis, S. aureus and Streptococcus mutans to glass. Both biofilm 
adhesion and biofilm aggregation are negatively affected after eDNA removal in S. mutans, S. 
epidermidis, P. aeruginosa and E. coli [58]. 
The adhesion of single bacterial cells to a surface consists of two distinct phases, both 
of them influenced by the presence or absence of eDNA on the cell surface. First, the bacterial 
cells come into contact with surfaces according to their physico-chemical properties; then, the 
adhesins anchor the cells more firmly to the surface through specific interactions. In the first 
phase, the eDNA adsorbs to the surface of single bacterial cells in long loop structures that 
extend from the surface of the cell to a distance sufficient to bridge the weak repulsive forces 
that separates the cell from the substratum. Secondly, eDNA on the cell surface mediates acid-
base interactions that are favorable for the adhesion of cells to the substratum [54,57].  
Most cells are negatively charged, including bacteria. Thus, adsorption of cations such 
as Ca2+ on the cell surface decreases electrostatic repulsion, aiding adhesion and aggregation 
[60]. eDNA, as a negatively charged molecule (due to the phosphates in the deoxyribose 
backbone [61]), presents the ability to bind cations via electrostatic interactions (similarly to 
chelators such as ethylenediamine tetraacetic acid (EDTA) [61,62]). Hence, in the presence of 
Ca2+, eDNA and cells further adhere and aggregate (Figure 1.9.A) and Figure 1.9.B)). In 
contrast, removal of the eDNA leads to disruption of the biofilm matrix, since the acid-base 
interactions (present in the interactions between cells [59]) and ionic-bridging are negatively 
affected and subsequently bacterial cell-to-cell interactions decrease (Figure 1.9.C) and Figure 
1.9.D)) [57]. 
 
Figure 1.9. Removal of eDNA influences acid-base interactions (named AB) B,D) and Ca2+ mediated cationic 
bridging between bacterial cells and consequently A,C) bacterial aggregation. Adapted from [57]. 
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Adhered eDNA on hydrophobic or low energy surfaces plays an influential role in 
promoting aggregation by repelling water and attracting adjacent bacteria. In the biofilm matrix, 
eDNA is the longest molecule [58] and binds with various biopolymers (polysaccharides and 
proteins – such as Beta toxin in the matrix of S. aureus biofilms and integrin host factor (IHF) 
in the biofilm matrix of numerous of the α-proteobacteria and γ-proteobacteria) and 
metabolites (phenazines – such as pyocyanin, a molecule produced by P. aeruginosa) [42, 
57,59], providing structural integrity and stability (Figure 1.10.A), Figure 1.10.B), Figure 
1.10.D) and Figure 1.10.F)) [57].  
The importance of eDNA for structural stability is typically demonstrated by 
disintegration of biofilms after DNase treatment [54]. In addition, some studies have also 
shown that adding DNA to bacterial cultures can stimulate biofilm formation. In some biofilms, 
eDNA also plays a role in modulating biofilm dispersal while ensuring that the existing biofilm 
structure remains intact [34,54,59,63].  
It is noteworthy that the importance of eDNA to the structural stability (specifically for 
cellular aggregation) of the biofilm can not necessarily be judged from the relative abundance 
of eDNA in the EPS matrix. For instance, eDNA is essential for biofilm formation of S. aureus 
and S. epidermidis, though present in larger quantities in the biofilms matrix formed by S. 
aureus [54].  
eDNA also guides motility in biofilms through unspecific and specific interactions [54]. 
For instance, an extensive range of Gram negative bacteria presents Type IV pili (like P. 
aeruginosa), that bind to eDNA, playing a role in both bacterial adhesion and eDNA-guided 
motility (Figure 1.10.C)) [54,59].  
Substantial proportions of most bacterial genomes consist of horizontally acquired 
genes. Horizontal gene transfer is a vital source of new genetic material for bacterial evolution 
and enhances the biofilms efficiency. In fact, this sharing of genetic material leads to beneficial 
adaptations such as antibiotic resistance (even though this is not necessarily genetic, it can 
also be the result of the diversity of metabolic states among the cells in the biofilm) or 
pathogenicity. Horizontal gene transfer is facilitated by a biofilm lifestyle, which is characterized 
by the existence of a mixed population at high bacterial density. The lysis of a subpopulation of 
cells during biofilm formation appears to be a common occurrence and the eDNA liberated by 
these events is available for horizontal gene transfer to competent cells in the environment [54, 
64,65].  
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According to Schooling et al. [66], eDNA interacts with biofilm-derived membrane 
vesicles (MV) (found within the matrices of Gram negative and mixed biofilms) forming mobile 
complexes, DNA-MV, able to affect cell adhesion and possibly involved in transfer of genetic 
information (Figure 1.10.E)). 
eDNA plays a direct role in protection against host defense systems, by chelating 
cationic antimicrobial peptides produced by the immune system [54]. In addition, eDNA also 
plays an indirect role in antimicrobial resistance by triggering expression of genes leading to 
elevated antibiotic resistance due to the lack of some divalent cations (such as Mg2+) [54,57].  
eDNA also influences the viscoelastic properties of biofilms, increasing the viscosity 
and, subsequently, the “sticky” character of biofilm matrix/slime. In this sense, the release of 
eDNA (at sub-inhibitory concentrations, since DNA is toxic at high concentrations [61]) 
promotes mechanical strength and protection of biofilms from biocides, grazing and shear 
stress [57,63,65].  
Ultimately, eDNA can work both in favor and against infecting bacteria. In fact, too 
much eDNA can strip Ca2+ and Mg2+ from the bacterial surface, leading to cell lysis caused by 
membrane disruption. Besides that, eDNA can alert the mammalian immune system to the 
existence of invading microorganisms, since the host organism is able to differentiate between 
self-produced DNA and bacterial DNA [54]. 
 
 
Figure 1.10. Interactions between eDNA and other matrix components. Adapted from [59]. 
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1.4. Anti-biofilm strategies 
In contemporary medicine, biofilm-related infections have become an increasingly 
prevalent problem [67], since most bacterial infections in human are correlated with biofilms 
[68]. In order to decrease the occurrence of these infections, factors that disrupt biofilm 
structure, lead to biofilm growth inhibition or biofilm eradication have been the topic of intense 
attention [67]. These factors may be physical, biological or chemical and influence the biofilm 
structure via various mechanisms and with different efficiencies [67,69]. 
Anti-biofilm strategies can be categorized in four main working mechanisms; 
prevention, which includes the bioengineering approaches that consist of altering the 
biomaterials used in medical devices to make them resistant to biofilm formation [70]; 
weakening; disruption; and last; direct killing (Figure 1.11). However, the general consensus is 
that a combination of these strategies will probably be most efficient [13]. In fact, an ideal anti-
biofilm strategy should involve multidisciplinary approaches or combinations thereof, to prevent 
the initial adhesion step and disintegrate any of the pre-formed biofilm. Realistically, there is no 
universal anti-biofilm method and some of the selection criteria are costs, site of application, 
delivery at site, dosing, frequency of application, specificity, contact time, biofilm stage and 
heterogeneity, residual effect, nature of biofilm (static or dynamic) and safety guidelines (if any) 
[69]. 
 
 
Figure 1.11. Anti-biofilm strategies. Adapted from [13]. 
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1.4.2. Biofilm prevention 
The ideal defense against infection is prevention. By preventing initial adhesion, not 
only host defenses are more efficient in the phagocytosis of bacteria, but also antibiotics show 
optimal efficacy [13]. However, the presence of a foreign body on the infection site produces a 
slight inflammation, making it almost impossible to detect the initial bacteria. Thus, when the 
inflammatory process is identified, the biofilm structure is already mature and difficult to 
eradicate [13,68]. Accordingly, preventive strategies are only suitable in the prophylactic 
setting [13]. 
Nowadays, preventive strategies are already applied in catheters and orthopedic 
implants with variable success rates [13,39]. The selection of the approach depends on 
whether the implant is easily accessible in the body or not. In the first situation, surfaces can 
be treated with ultraviolet (UV) light and then sterilized non-invasively. On the other hand, if 
surfaces are not reachable, hypothetic targets to prevent biofilm formation include flagella, pili, 
eDNA, polysaccharides and surface properties involved in the initial attachment of bacterial 
cells. The prevention of biofilm formation can be achieved using different methods, for example 
through inhibition of specific regulatory pathways for the production of the aforementioned 
elements or application of enzymes that degrade the components of EPS matrix or use of 
neutralizing antibodies addressed at these molecules [13].  
The development of anti-infective biomaterials has become a primary strategy to 
prevent the occurrence of infections in medical devices [18]. Improving biomaterial anti-biofilm 
properties remains the most effective and promising strategy to prevent the morbidity and 
mortality associated with biofilm infections. In order to make biomaterial surfaces resistant to 
biofilm formation it is possible to coat the surface with bactericidal/bacteriostatic substances 
such as antibiotics, heavy metal silver and furanones [70]. Evidently, the substances added to 
superficial coatings should be selected to provide a broad activity against the microorganisms 
commonly found in the target application area [71]. PLGA, for instance, has generated a 
pronounced interest due to their favourable properties, easy formulation into different devices 
for carrying a variety of drug classes and also proteins and peptides [72], while it already has 
been approved by the Food and Drug Administration (FDA) for drug delivery [73]. One of the 
shortcomings of the bactericidal surfaces is that they could be covered by macromolecules and 
dead microorganisms, therefore losing their antimicrobial function [13,70].  
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The number of bacteria that may adhere on biomaterial surfaces is greatly influenced 
by the physicochemical properties of the biomaterial. So, altering the surface properties of 
indwelling medical devices is one of the main focuses to prevent or decrease biofilm infections. 
The surface properties of biomaterials or medical devices can be changed by coating 
application, such as heparin coatings, trimethylsilane plasma nanocoatings and polymer brush 
coatings (the most studied ones being made from poly(ethylene oxide) (PEO)), or surface 
modification such as surface hydrophobicity and texture, to create the desired anti-adhesion 
characteristics without altering the bulk properties of materials [16,39,70].  
In spite of the extensive offer of new materials to reduce the susceptibility of medical 
devices, the information available on their respective clinical effectiveness is often unclear and 
recurrently preclinical studies provide the only supporting data. Additionally, existing clinical 
studies are frequently poorly structured and show questionable or inconsistent results [18]. 
 
1.4.3. Biofilm weakening 
If biofilm formation cannot be prevented, another method is to defuse bacteria inside 
the biofilm. It is necessary to highlight that many of these strategies are species-specific or 
even strain-specific. Furthermore, all efforts (both in vitro and in vivo) to determine the 
efficiency of biofilm-weakening compounds have been achieved using drugs acting on 
immature and developing biofilms [13]. 
Many bacterial species possess well-characterized virulence factors, such as 
rhamnolipids for P. aeruginosa, alpha-haemolysin for S. aureus and β-lactamase for both 
species. By developing specific antibodies or compounds that bind to the virulence factor, the 
pathogen might lose its virulence and can be more easily eradicated by the host defence 
system or antibiotics. This method presents some drawbacks, such as the possibility of 
stimulating immunopathology since only single virulence factors are targeted (there is a 
increased inflammation due to an immune-complex-mediated reaction), and it is likely to only 
be effective in the initial stages of infection, since these factors are lost during adaptation [13]. 
As iron is a critical factor in the struggle between the pathogen and the host and has 
been shown to be an important signalling factor in biofilm formation (for P. aeruginosa), 
antimicrobial approaches that target bacterial iron metabolism are being developed. In fact, 
some of these antimicrobial substances have already been tested and showed good anti-
biofilm activity against P. aeruginosa in vitro [13]. 
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Among the main mechanisms leading to biofilm maturation (of bacteria or fungi) are 
quorum sensing (QS) signals [68,74]. QS has been shown to regulate the expression of 
numerous virulence factors in both Gram-negative (related to the stabilization of biofilms) and 
Gram-positive bacteria (linked to the destabilization of biofilms). QS inhibitors (QSIs) are 
distinct from conventional antibiotics since they do not focus on the growth and on the 
elementary life processes of bacteria, but on the reduction of bacterial virulence. Therefore, 
possible development of bacterial resistance to QSIs is expected to be lower and these drugs 
are likely to be efficient against bacteria that are already resistant to conventional antibiotics. 
Additionally, several QSIs contribute to the increase of bacterial susceptibility to conventional 
antibiotics. Despite it being demonstrated that QSIs work equivalently well on both planktonic 
bacteria and bacteria in biofilms, they are typically species-specific [13]. 
Potential future strategies for weakening biofilms will probably involve the control of 
gene regulation networks by cyclic diguanosine-5’-monophosphateor (c-di-GMP) or small RNAs 
(sRNAs) (a class of regulatory biomolecules abundant in many bacterial species) inhibitors, as 
both signalling pathways act in a synchronized way on the same targets with the purpose of 
stimulating biofilm formation [13]. 
Finally, the association of chelators of divalent cations such as citrate or EDTA and 
biocides has also been proposed, based on their ability to destabilize biofilm matrix [74]. 
 
1.4.4. Biofilm disruption 
Disrupting the EPS matrix can weaken and disperse biofilms [70]. In fact, the 
disruption of the biofilm reverses the physical tolerance of the bacteria within the biofilm, 
forcing the bacterial cells (or part of them) to live in the planktonic state (Figure 1.12) [75].  
 
 
Figure 1.12. Schematic illustration of the biofilm disassembly. Taken from [75]. 
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In the planktonic state, the bacteria are significantly less resistant to antimicrobial 
substances (most of the currently used drugs have been developed and optimized to kill 
planktonic microorganisms [74]) and phagocytosis by polymorphonuclear leukocytes [13]. 
If the surface is not accessible, as in the case of implants, biofilm disruption by 
ultrasound treatment is one of the possibilities being studied. However, there are some 
disadvantages in such approaches, namely that biofilm disruption can lead to spreading of the 
infection (hence the important of antibiotic prophylaxis), and the ultraviolet light or ultrasound 
waves are absorbed by the host tissue mitigating the effect of these strategies and may have a 
destructive effect on host tissues [13]. 
Another method to encourage biofilm dispersal is by decreasing the c-di-GMP levels 
[13]. This molecule is responsible for the transformation from the motile to the sessile state of 
microbial cells towards the establishment of biofilms [68]. In this sense, diminishing c-di-GMP 
levels (controlling c-di-GMP signalling pathways in bacteria) offers a new alternative to clinically 
manage biofilm formation and dispersal [13,68].  
Direct dispersal of biofilms can also be accomplished by decreasing the adhesiveness 
of bacteria. Elements that cause disruption of the exopolysaccharide of bacterial biofilms (such 
as the alginate oligomer (oligoG) that binds to a bacterial surface, inducing microbial 
aggregation, decreasing microbial motility and swarming, and consequently affecting biofilm 
disruption [76]) are good possibilities [13,74].  
Lastly, it is important to emphasize that up to this moment, biofilm dispersal strategies 
(except when disrupting enzymes are applied) have only been tested in vitro [13].  
 
1.4.4.1. Biofilm disruption enzymes 
Since it has been postulated that the EPS matrix may contribute to the resistance of 
biofilm cells to antimicrobials, it would follow that targeting the EPS would aid in the design of 
infection targeting strategies [39]. The biofilm matrix is an excellent target for anti-biofilm 
treatments, due to the fact that the biofilm matrix is highly exposed to the environment (which 
is not as much the case for bacterial cells therein) and also because the biofilm structure is 
intrinsically porous [54]. As bacterial lyses in biofilms is common (Figure 1.13), one possible 
strategy to disrupt the biofilm structure could be achieved via the degradation of individual 
biofilm compounds by their own enzymes (potential therapeutic agents) [67,77].  
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Figure 1.13. Schematic representation of several matrix-degrading enzymes used for biofilm inhibition and 
dispersal. Taken from [77]. 
 
Strategies using enzymatic degradation of matrix components have been identified as 
efficient ways to disperse biofilms [74]. The mechanism of biofilm dispersal is an intrinsic 
phenomenon employed by several bacterial species. DNase thermonuclease, glycoside 
hydrolase dispersin B and alginate lyase are some examples of enzymes produced by S. 
aureus, Aggregatibacter actinomycetemcomitans and P. aeruginosa, respectively, with the goal 
of initiating active dispersion of the biofilm, ensuring bacterial survival and disease 
transmission [77]. In this context, various enzymes have been studied aiming at biofilm 
disruption (Table 1.5). 
 
Table 1.5. Biofilm-disrupting enzymes 
Enzyme 
Target in the biofilm 
matrix 
Bacteria in which the treatment is effective 
in vitro in vivo 
Dispersin B PNAG [75,78]  S. aureus (growing biofilms), S. 
epidermidis [31,77], E. coli, 
Yersinia pestis [77], P. 
fluorescencens [13] 
S. aureus (combined with 
triclosan) [77] 
Alginate lyase Alginate [77] P. aeruginosa [77] P. aeruginosa 
(coadministered with 
amikacin [77] or 
gentamicin [13]) 
Lysostaphin Pentaglycine bridges 
[75,79] 
S. aureus, S. epidermidis, MRSA 
[67] 
MRSA (in the presence of 
nafcillin) [67] 
Serratopeptidase 
(SPEP) 
 
Ami4b autolysin, 
internalin B, and ActA 
[80] 
L. monocytogenes [80] P. aeruginosa and S. 
epidermidis (combined 
with ofloxacin), Listeria 
monocytogenes [77] 
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DNase eDNA [77] NucB: Bacillus subtilis, E. coli, 
Micrococcus luteus [77] 
Nuc: S. aureus [77,81], H. 
influenza, Klebsiella pneumonia, 
P. aeruginosa, Acinetobacter 
baumannii, [81] 
Streptococcus pyogenes [67] 
 
DNase 1L2 eDNA S. aureus, P. aeruginosa [67]  
Recombinant 
human DNase I 
(rhDNase I) 
eDNA [77] S. aureus, S. epidermidis, 
Streptococcus pneumoniae, P. 
aeruginosa [77] 
P. aeruginosa (rhDNase I) 
[77] 
Protease Esp Unknown [75] S. aureus [77,82] S. aureus [77] 
Proteinase K Biofilm-associated 
protein 
S. aureus [77]  
α - Amylases α-1,4-glicosidic bond in 
glycogen, starch, 
maltooligosaccharides 
[83] 
S. aureus [67,81], V. cholerae, 
P. aeruginosa [81] 
 
Lactonase Acylated homoserine 
lactones (AHLs) [84] 
P. aeruginosa [67]  
 
However, it is necessary to emphasize that enzyme-based approaches have some 
limitations mostly regarding their restricted spectrum of action, the effectiveness of the 
individual mechanisms that is highly dependent on the matrix composition of the strain in 
question [85] and the risk of immunization against these molecules [74]. In addition, the in 
vivo efficacy of this method is not well established and treating hosts with proteins could cause 
inflammatory and allergic reactions, which could affect the enzymes therapeutic potential [70]. 
 
1.4.4.1.1. eDNA as a target in biofilm treatment 
The recognition of the role of eDNA in providing mechanical stability to biofilms (Figure 
1.14.A)) makes this molecule an attractive target for new approaches to anti-biofilm treatments 
[12,55]. As stated before, eDNA is an important component of the EPS matrix [70,77] and the 
use of nucleases as an anti-biofilm strategy has been explored against various bacterial strains 
[77]. Interestingly, some bacteria already use this strategy themselves, for example, Bacillus 
licheniformis releases a self-produced extracellular DNase in order to disperse the biofilms of 
its competitors [54]. 
DNase I is an endonuclease that digests DNA through the hydrolysis of the 
phosphodiester bonds [59,86]. The enzyme activity is strictly dependent on Ca2+ (stabilizes two 
disulfide bridges in the DNase I) and is activated by Mg2+ or Mn2+ ions [86-88].  
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Degradation of eDNA by DNase I disrupts the EPS matrix of adhering bacteria at the 
biomaterial-bacteria interface, hence interfering with the first phase of biofilm formation (initial 
adhesion) and preventing formation of a mature biofilm (Figure 1.14.B)) [12,58].  When a 
bacterium adheres to a surface, degradation of the eDNA leads to disintegration of the EPS 
formed during growth of the adhering bacteria, leaving them incapable to evolve into a 
structurally stable biofilm. Additionally, the presence of DNase I at the bacterial-substratum 
interface interferes with the aggregation of bacteria and cell-cell interactions at the substratum 
surface, since eDNA is an essential component in both processes [58]. Therefore, biofilms 
formed in the presence of DNase exhibit reduced biomass resulting from a reduced number 
and size of microcolonies within the biofilm, and exhibit decreased antibiotic tolerance [77]. 
Consequently, the therapeutic potential of biofilm dispersing enzymes, particularly DNase, is of 
increasing research interest. Not only does DNase treatment have the potential to dissolve 
bacterial biofilms, but pre-treatment with DNase has been demonstrated to sensitize some 
biofilms to eradication by topical antiseptics, as well as enhancing the effect of antibiotic 
treatments by altering the biofilm structure to allow increased penetration of antibiotics. The 
dispersion of the biofilm by applying DNase could be useful to the prevention of biofouling in 
several systems [54].  
 
 
Figure 1.14. Mechanism of biofilm dispersal caused by DNase I. A) eDNA acting as a bridge between a 
bacterial cell surface and various biopolymers in EPS. B) Disruption of EPS by DNase I coating attacking the 
eDNA component of the EPS, preventing bacterial adhesion to the substratum surface. Adapted from [58]. 
 
1.4.5. Biofilm Killing  
The most straightforward anti-biofilm strategy is the direct killing of pathogens. For 
example, ethanol or hydrochloric acid are used as topical therapy of biofilms on intravenous 
catheters [13].  
Introduction 
  Chapter 1 | 29 
 
Gallium nitrate is approved by the FDA for scanning in medical diagnostics and is an 
investigational agent that treats biofilm infections by directly killing bacteria, more precisely P. 
aeruginosa (in vitro and in vivo using animal models). If efficient, this antibacterial agent could 
be extremely useful in patients with cystic fibrosis, decreasing the density of sputum [13]. 
Bacteriophages are viruses that are able to infect and replicate within bacteria, killing 
both antibiotic-sensitive and antibiotic-resistant bacteria (host bacterial cell). Some phages also 
produce enzymes that degrade the biofilm matrix, inducing the dispersion of the biofilm 
[13,68]. 
 
1.4.6. Combined strategies 
Occasionally, for the efficient treatment of biofilm-related infections, a combination of 
different strategies is necessary. 
Essentially all biofilm dispersal approaches will need to have simultaneous antibiotic 
treatment to eradicate the planktonic bacterial cells that are released after dispersion in order 
to avoid the spread of infection to other parts of the body [13], the return of these cells to the 
biomaterials surface and the following development of new biofilms. For instance, in the case 
of dispersal by bacteriophages, the process could be improved by combining bacteriophages 
with antibacterial drugs [13,68]. Furthermore, the combination of DNase I with certain 
antibiotics (such as azithromycin, rifampin, levooxacin, ampicillin and cefotaxime) increases 
the bacterial susceptibility [67]. 
Since several studies showed that antibiotic monotherapy is considerably less effective 
against biofilms infections [68], another possibility to facilitate the effective eradication of 
biofilms is the combination of high concentrations of antibiotics during a proper period of time 
in the infection site. Preferably, the used antimicrobial agents should be sensitive, well-
penetrating in profounder levels of biofilms and preserve their activity in these locations 
[13,68]. In addition, the route of antibiotics administration could also be mixed. Coupling of 
systemic and topical antibiotic treatments can present superior results in patients with biofilm 
infections suitable for topical treatment of high doses of antibiotics [68]. 
Mechanisms exploiting external metabolic and chemical stimuli, combined with 
antibiotics or engineered bacteriophages are being proposed for treating persistent cells [13]. 
Lastly, weakening of the EPS matrix by phage-encoded depolymerases might also 
increase the effects of antimicrobial drugs [13]. 
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2.1. Particle preparation 
2.1.1. Particle formulations and dimension 
Inulin-DNase I mixed (with a ratio of 4:1) and single powders of inulin and DNase I 
were produced by dissolving DNase I (from bovine pancreas, purity ≥ 86%, 400 Kunitz 
units/mg, Sigma Aldrich, St. Louis, MO, USA) and inulin (with a degree of polymerization of 
23, Sensus, Roosendaal, The Netherlands) in water up to a total concentration of 5 mg/ml. 
The solutions were spray-dried using a B-90 spray-dryer (Büchi Labortechnik AG, Flawil, 
Switzerland) in combination with a B-296 dehumidifier and a two-fluid nozzle. The inlet air 
temperature was set at 80 °C, the aspirator at 150 l/min, liquid feed flow at 1 ml/min and 
atomizing air flow at 600 ln hr-1.  
The particle size distribution of the spray dried trehalose was measured by laser 
diffraction analysis (HELOS, Sympatec, Clausthal-Zellerfeld, Germany). Measurements were 
performed using a HELOS laser diffraction sensor with an R1 (0.1/0.18-35 µm) lens, and a 
RODOS for powder dispersion (Sympatec GmbH, Clausthal-Zellerfeld, Germany) at 3 bar. Laser 
diffraction data was analyzed with the Fraunhofer method. 
 
2.2. Surface coating 
2.2.1. Titanium substrate preparation 
Before applying the different PLGA coatings to the titanium surface (1.50 cm × 1.50 
cm ×  0.10 cm, Goodfellow Cambridge Ltd., Cambridge, United Kingdom), the titanium 
substrata were sonicated using a 35 kHz ultrasonic bath (Transsonic TP 690-A, Elma®, 
Germany) for 3 min in 2% RBS35 (Omnilabo International B.V., Breda, The Netherlands). Then, 
in order to eliminate any traces of the alkaline cleaning agent, titanium plates were rinsed 
several times with ultrapure water (18.2 MΩ cm-1, Arium®, 611 DI, Sartorius, Göttingen, 
Germany), followed by methanol (Sigma-Aldrich, purity ≥ 99.93%, Venezuela) and again 
ultrapure water. After multiple usage of titanium substrata, the procedure described above was 
preceded by additional cleaning that consisted of sonication in a 35 kHz ultrasonic bath for 3 
min in acetone (VWR, BDH, Prolabo®) and polishing the surface manually with a water-based 
monocrystaline diamond suspension (MetaDi® 1 µm, Buehler, Lake Bluff, USA) for 
approximately 30 s in a basic lapping with a polishing cloth. 
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2.2.2. Coating of the titanium substrata 
The polymer used to incorporate the different particle formulations was PLGA 
(PURASORB® PDLG 5002, Corbion, Diemen, The Netherlands) with a copolymer ratio of 
50:50 [lactide-to-glycolide], an inherent viscosity of 0.2 and an average molecular weight (Mwb) 
of 17 kDa.  
PLGA was dissolved (10% w/v) in acetonitrile (EMPLURA®, purity ≥ 99%, Merck KGaA, 
Darmstadt, Germany) under continuous agitation at 250 rpm overnight, followed by the 
addition of the different particle formulations (section 2.1.1.) (1% w/v). After 3 h, 100 µl of the 
suspension was applied to the titanium substrata, which were then left to dry overnight at room 
temperature. In the case of titanium substrata coated with only PLGA, the PLGA solution in 
acetonitrile was directly applied to the surface (Figure 2.1). Coated substrata were stored at 
room temperature and used within a maximum time period of 5 d.  
 
 
Figure 2.1. Schematic representation of the procedure used to coat each titanium substrata (only PLGA, 
PLGA-DNase I, PLGA-DNase I (1/5) and PLGA-inulin packaged DNase I). 
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In quantitative terms, each coating consisted of 4.4 mg PLGA/cm2, containing 0.44 
mg of particles/cm2 (for the PLGA-inulin and PLGA-DNase I coatings) or 0.088 mg of DNase 
I/cm2 (for the PLGA-DNase I (1/5) coating). PLGA-inulin packaged DNase I contained 0.352 
mg of inulin/cm2 and the same amount of DNase I as the PLGA-DNase I (1/5) coating.  
 
2.2.3. Coatings roughness and thickness 
The roughness of the uncoated titanium surface and each PLGA coatings (section 
2.2.2.) was determined using white light interferometry (Proscan 2000, Scantron Industrial 
Products Ltd., Taunton, Somerset, UK). The samples were placed in a holder and mounted on 
the profilometer with the use of double-sided sticky tape. The sample was put below the laser 
to obtain height images in three dimensions of an area of 4 mm2. The height was measured in 
this area every 2 µm. The average roughness (Ra), obtained from the acquired images, 
indicates the average distance of the roughness profile to the centre plane of the profile.  
To determine the thickness of the different PLGA coatings (section 2.2.2.), a cut was 
made in each coating, exposing the underlying titanium surface, and the depth of the cuts was 
measured (difference in height between the surface of the PLGA coating and the titanium 
surface). 
All measurements were performed in triplicate on random locations of independently 
prepared coatings. 
 
2.2.4. Coatings degradation time 
In order to determine the degradation time of each PLGA coating (section 2.2.2.), 
samples were placed in 7 ml of a phosphate-buffered saline (PBS) (150 mM NaCl, 5 mM 
K2HPO4, 5 mM KH2PO4, pH 7.0) solution in a 6-well polystyrene plate (Cellstar®, Greiner Bio-
One, Netherlands), incubated at 37 °C and 60 rpm (New Brunswick Scientific CO., INC. 
Edison, New Jersey, USA).  
Pictures (Canon, lens 28-35mm, Japan) of the various PLGA coatings were taken 
every 7 d, until no residue of the coating could be macroscopically observed.  
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2.3. DNase I release kinetics 
2.3.1. DNase I calibration curve 
A standard curve was constructed using several solutions of DNase I with known 
concentrations, ranging from 0 µg/ml (reference) to 150 µg/ml, in PBS. The absorbance (Abs) 
was measured using a Nanodrop® spectrophotometer (ND-1000, NanoDrop Technologies, 
Inc., Wilmington, DE) at 595 nm, after mixing 100 µl of each solution with 100 µl of Bradford 
reagent (Sigma Aldrich, USA) and vortexing. Demineralized water was used as blank.  
 
2.3.2. Inulin calibration curve 
A calibration curve of the absorbance of inulin solutions with known concentrations 
was constructed, ranging from 0 µg/ml (reference) to 100 µg/ml inulin, in PBS. To measure 
the absorbance, 1 ml of each solution was mixed with 2 ml anthrone reagent (Sigma Aldrich) 
(commonly used to determine carbohydrate concentrations [51,89]), prepared at a 
concentration of 1 mg/ml in sulfuric acid (H2SO4, 95-97%, Merck KGaA, Darmstadt, Germany), 
and vortexed. After letting the mixture cool down for 30 min, it was transferred to a plastic 
cuvette and the absorbance at 630 nm was measured (Smart SpecTM 3000, Bio-Rad, 
Hercules, Ca, USA).  
 
2.3.3. DNase I release kinetics 
In order to determine the release kinetics of DNase I from the protective PLGA coating, 
titanium substrata coated with PLGA-DNase I or PLGA-inulin packaged DNase I, were placed in 
a 12-well polystyrene plate (Cellstar®, Greiner Bio-One, Netherlands) submersed in 2 ml PBS 
and incubated at 37 °C and 60 rpm. 
At several time points (1 h, 4 h, 8 h, 24 h, 48 h, 72 h, 96 h and 120 h), the PBS was 
completely removed, stored and then replaced for the same amount of fresh PBS. Afterwards, 
the amount of released DNase I was measured using spectrophotometry. Briefly, 100 µl PBS 
was mixed with 100 µl Bradford reagent and the absorbance was measured using a 
NanoDrop® spectrophotometer at 595 nm, after vortexing each sample. PBS without DNase I 
was used as a reference and demineralized water was used as blank. Whenever needed, 
samples were diluted 2 times in PBS and the absorbance was measured again.  
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The calibration curve (section 2.3.2.) was used to determine the amount of DNase I 
released by the different samples.  
The analysis was based on the results of three experiments using titanium with 
separately prepared PLGA-DNase I or PLGA-inulin packaged DNase I coatings. 
 
2.3.4. Inulin release kinetics 
In the case of the titanium coated with PLGA-inulin packaged DNase I, the amount of 
inulin released was determined using the anthrone assay. Anthrone reagent was freshly 
prepared for each measurement at a concentration of 1 mg/ml in sulfuric acid and the 
absorbance for each sample was measured as described in 2.3.2. Whenever necessary, 
samples were diluted 2 times in PBS and measured again.  
The calibration curve was used to determine the concentration of inulin released by 
the samples.  
 
2.3.5. Scanning electron microscopy 
To study the coating structure and degradation in more detail, images were collected 
using scanning electron microscopy (SEM) (Phenom Pure Desktop SEM, PhenomWorld, 
Eindhoven, the Netherlands). Before image collection, the titanium samples coated with PLGA-
DNase I or PLGA-inulin packaged DNase I after 1 h and 120 h of immersion in PBS were 
washed with ultrapure water and after drying, were placed on the top of double-sided sticky 
carbon tape on metal disks, followed by sputtercoating with approximately 10 nm 
gold/palladium (SC7620 Mini Sputter Coater, Quorum Technologies Ltd, United Kingdom). 
 
2.3.6. Initial burst release 
To control the initial burst release of DNase I two different approaches were used as 
described below. The DNase I release kinetics for both strategies were determined as 
previously described (section 2.3.3). 
The first approach consisted in applying an extra layer of only PLGA (prepared under 
the same conditions as described in 2.2.2.) over already coated titanium substrata with PLGA-
DNase I (Figure 2.A)) or PLGA-inulin packaged DNase I (Figure 2.B)). 
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The second approach consisted of increasing the thickness of the PLGA coating. To 
this extend, coatings of PLGA-DNase I or PLGA-inulin packaged DNase I were applied using 
200 µl (instead of 100 µl) of the respective solutions of PLGA, (section 2.2.2) diluted two times 
(in order to keep the same amount of DNase I or inulin and DNase I, respectively, as used 
before).  
 
 
Figure 2.2. Schematic illustration of the procedure used to avoid the initial burst release of DNase I from 
titanium coated with A) PLGA-DNase I and B) PLGA-inulin packaged DNase I (first approach). 
 
2.4. Bacterial culture and harvesting 
2.4.1. Bacterial strains 
Two clinical isolates of S. aureus were used in this study, S. aureus ATCC 12600 and 
S. aureus Newman D2C (also known as S. aureus ATCC 25904). Both strains were supplied 
by the American Type Culture Collection (ATCC, Manassas, USA). The first strain (ATCC 
12600) was isolated from pleural fluid, while the second strain (Newman D2C) was obtained in 
1952 from a human infection (a case of secondarily infected tubercular osteomyelitis in a men 
[90]) and has been used in animal models of staphylococcal disease due to its vigorous 
virulence phenotype [10].  
S. aureus ATCC 12600 and S. aureus Newman D2C were selected as representatives 
of the genera staphylococcus for their capacity to develop biofilms with an EPS matrix [53], 
and more importantly, because they are common colonizers of biomaterials and biomedical 
device surfaces. 
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To generate a green fluorescent protein (GFP) expressing S. aureus ATCC 12600 and 
S. aureus Newman D2C, the pMV158GFP [91] containing optimized GFP, under the control of 
the constitutively expressed MalP promotor [92], was introduced into competent bacterial cells 
by electroporation, as described by Li et al. [93]. The selection of subsequent transformants 
was performed on tryptone soya broth (TSB) (OXOID, Basingstoke, UK) agar (bactoagar, BD Le 
Pont de Claix, France) plates containing 10 µg/ml of tetracycline (hydrochloride, purity ≥ 95%, 
Sigma). S. aureus ATCC 12600 and S. aureus Newman D2C containing the pMV158GFP (S. 
aureus ATCC 12600GFP and S. aureus NewmanGFP, respectively) showed constitutive GFP 
expression, thus allowing an easy quantification of adhesion numbers and biofilm formation 
without additional staining [12]. 
Both strains were stored in 7% dimethyl sulfoxide (DMSO) at -80 °C.  
 
2.4.2. Growth conditions  
From a frozen stock, staphylococci were cultured overnight aerobically at 37 °C on 
TSB agar plates containing 10 µg/ml tetracycline in aerobic conditions. For pre-cultures, three 
single colonies were inoculated in 10 ml TSB containing 10 µg/ml tetracycline and incubated 
at 37 °C for 24 h (conditions routinely used in the growth of S. aureus strains). Main cultures 
were grown by diluting the pre-cultures in 200 ml of TSB in absence of antibiotics, which were 
then allowed to grow for 16 h at 37 °C prior to harvesting. 
 
2.4.3. Bacterial harvesting 
Bacteria were harvested by centrifugation at 5000 × g for 5 min at 10 °C (Beckman 
Coulter®, JLA – 16.250, USA) and washed twice in 10 mL PBS, before being resuspended in 
10 mL of PBS and sonicated at 30 W (Vibra Cell model 375, Sonics and Materials Inc., 
Danbury, CT, USA) for 3 × 10 s in order to obtain single cells, i.e. to break existing aggregates. 
Sonication was performed discontinuously (with 30 s breaks in between) while being cooled in 
an ice-water bath to avoid excessive heat development. 
Bacterial densities were determined using a Bürker-Türk hemocytometer and an 
Olympus light microscope with × 40 magnification (Olympus Co., Tokyo, Japan). Suspensions 
were diluted to 3 × 108 bacteria/ml in PBS for all experiments. 
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2.5. Initial bacterial adhesion and biofilm growth 
2.5.1. Initial bacterial adhesion 
For initial adhesion experiments, 5 ml of bacterial suspension supplemented with 1 
mM CaCl2.2H2O (BOOM, purity ≥ 99%, Germany) and 10 mM MgCl2.6H2O (Sigma-Aldrich, 
purity ≥ 99%) was added to the various substrata in 6-well polystyrene cell suspension culture 
plates and incubated at 37 °C and 60 rpm under aerobic conditions for 1 h. 
After 1 h, samples were rinsed in PBS (in order to remove non-adherent and/or 
loosely bound bacterial cells on the titanium surface – since loosely bound cells possibly 
interfere with microscopy imaging), placed into new 6-well plates with 5 ml PBS and analyzed 
using fluorescence microscopy (Leica DM4000B, Leica Microsystems GmbH, Heidelberg, 
Germany). Images were taken at three randomly chosen locations on each substrate using a 
40 × water immersion objective using filter sets only for GFP.  
The total number of adhering bacteria was determined using ImageJ (a Java-based 
image processing program developed at the National Institutes of Health (NIH)). 
All experiments were performed in triplicate with separately grown cultures. 
 
2.5.2. Biofilm growth 
Biofilm growth was started after 1 h of initial bacterial adhesion. To this end, samples 
were removed from bacterial suspensions, non-adhering cells were removed by rinsing 
with PBS and placed into new 6-well plates containing 5 ml TSB, supplemented with 1 mM 
CaCl2.2H2O, 10 mM MgCl2.6H2O and 10 µg/ml tetracycline. Next, samples were incubated for 
24 h, 72 h or 120 h at 37 °C and 60 rpm under aerobic conditions. Every 24 h, samples were 
removed and placed into new 6-well plates containing fresh TSB and the same supplements as 
mentioned above and were then incubated under the same conditions until the desired 
incubation time was reached.  
Biofilms grown on bare titanium and protective PLGA coatings were evaluated using 
both confocal laser scanning microscopy (CLSM) (Leica DMRXE TCS-SP2; Leica Microsystems 
Heidelberg GmbH, Heidelberg, Germany), as well as optical coherence tomography (OCT) 
(Telesto-II 1300, Thorlabs, Newton, NJ, USA). The use of OCT was necessary to rule out 
possible interference of DNase I with the fluorescence signal [12]. Again, all experiments were 
performed in triplicate with separately grown cultures. 
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After the incubation period, biofilm samples were carefully transferred to new 6-well 
plates containing 5 ml PBS and examined by CLSM and by OCT, in this order. 
Using CLSM, optical cross-sections of the biofilms were taken at three random 
locations of each surface with a 40 × ultra-long-working-distance objective (a water immersion 
lens). A Matlab (The MathWorks, Natick, MA, USA) based analysis program used for 
quantification of 3-dimensional (3D) biofilm structures, COMSTAT, was used to calculate the 
biovolumes of the image stacks [94,95]. 3-D images were constructed employing Icy, an open 
community platform for bioimage informatics. 
The images obtained using OCT were analyzed only qualitatively and processed using 
Fiji, an image-processing package based on ImageJ. 
 
2.6. U-2 OS adhesion and XTT assay using U-2 OS 
2.6.1. U-2 OS cell line 
The occurrence of potential adverse effects of the various PLGA coatings on 
mammalian cells was evaluated using U-2 OS osteoblast-like cells (ATCC number: HTB-96; 
obtained from LGC standards, Wesel, Germany), an immortalized human cell line derived from 
osteosarcoma cells.  
 
2.6.2. Growth conditions 
U-2 OS cells were routinely cultured in low-glucose Dulbecco's Modified Eagle's 
medium (DMEM) (Gibco, Life Technologies), supplemented with 10% fetal bovine serum (FBS) 
and 0.2 mM ascorbic acid-2-phosphate (AA2P) (DMEM+FBS). Cells were maintained at 37 °C 
in a humidified atmosphere with 5% CO2 and passaged at 95% confluence using 
trypsin/ethylenediaminetetraacetic (EDTA) (Gibco, Life Technologies). Harvested cells were 
counted using a Bürker-Türk haemocytometer and subsequently diluted to a concentration of 
4.3 x 104 cells per ml in growth medium and incubated at 37 °C and 5% CO2 during 24 h in 6-
well polystyrene plates with 5 ml of cell suspension. Subsequently, the 2,3-bis(2-methoxy-4-
nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay (AppliChem) and the cell 
adhesion assay were performed (Figure 2.3).  
Note that prior to all cell experiments all substrata were sterilized by placing them in 
70 % ethanol for 10 s. 
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2.6.3. XTT assay 
After 24 h incubation at 37 °C and 5% CO2, titanium samples were placed in a 12-well 
plate and covered with 2 ml of fresh DMEM+FBS. The medium in the 6-well plate in which the 
U-2 OS cells were incubated was replaced by 3 ml of new DMEM as well. Then, the XTT assay 
was performed using the U-2 OS cells above the substrata and the U-2 OS cells adhered to 
each well of the 6-well plate (cells surrounding the material) according to the procedure from 
AppliChem [96].  
First, a reaction solution was prepared by adding 0.1 ml of activation solution to 5 ml 
of XTT reagent. Next, 130 µl of the reaction solution was added to each well (6 wells 
containing the titanium substrata and 6 wells where the titanium substrata were incubated) 
and incubated at 37 °C and 5% CO2 for 3 h in the dark. The cell metabolism reduces the XTT 
tetrazolium salt to XTT formazan by mitochondrial dehydrogenases, thus resulting in a 
colorimetric change. The amount of water-soluble product generated from XTT is proportional 
to the number of metabolically active cells and was measured in a 96-microplate reader at 485 
nm (Fluostar OPTIMA, BMG Labtech) using 200 µl of each sample in duplicate [97]. In order 
to measure the reference absorbance (i.e. to measure non-specific readings) the absorbance of 
the samples was measured again at a wavelength of 690 nm and these values were 
subtracted from the 485 nm measurement.  
The XTT assay was performed three times with separately grown U-2 OS cells and 
different batches of coated samples. 
 
2.6.4. Cell adhesion assay  
After the XTT assay, substrata were prepared for immuno-cytochemical staining by 
fixation in 3.7% paraformaldehyde (Sigma Chemical Co.) in cytoskeleton stabilization buffer 
(0.1 M Pipes, 1 mM ethylene glycol tetra acetic acid (EGTA), 4% (w/v) polyethylene glycol 
8000, pH 6.9) and subsequent treatment with 0.5% Triton-X100 (Sigma, St. Louis, MO, USA) 
for 3 min.  
The fixated U-2 OS cells were stained using tetramethylrhodamine (TRITC)-Phalloidin 
(Sigma Chemical Co.) for quantitative analysis. To this end, after rinsing with PBS, substrata 
were incubated in 1 ml PBS containing 2 µg/ml TRITC-Phalloidin and 4 µg/ml DAPI (4,6-
diamidino-2-phenylindole,Sigma Chemical Co.) for 30 min in the dark.  
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Before being examined using fluorescence microscopy (using a 40 × water immersion 
objective and filter sets for TRITC-Phalloidin and DAPI), substrata were washed 4 times with 
PBS to remove any excess of dye. Images (three images on random locations) were taken and 
the number of adhering cells per cm2 on each sample was determined by counting the number 
of blue-stained nuclei. 
The cell adhesion assay was performed three times with independently grown U-2 OS 
cells and different batches of coated samples. 
 
 
Figure 2.3. Schematic representation of the procedure used to analyse the metabolic activity of U-2 OS cells 
around the material and cells adhered to the material (XTT assay), as well as the number of live cells in both 
cases (cell adhesion assay). 
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2.7. Pilot experiment: effect of gentamicin when 
combined with the PLGA coatings containing either DNase I 
or inulin-packaged DNase I 
2.7.1. Minimum inhibitory concentration and minimum 
bactericidal concentration  
The minimum inhibitory concentration (MIC) and the minimum bactericidal 
concentration (MBC) of gentamicin were determined using a modified broth macrodilution 
method, as described by the Clinical and Laboratory Standards Institute (CLSI) guidelines [98]. 
Planktonic cells of S. aureus ATCC 12600GFP and S. aureus Newman D2CGFP were 
obtained as described before (section 2.4.1., 2.4.2. – pre-cultures without tetracycline – and 
2.4.3). The final concentration of bacteria in each broth macrodilution tube was 5×10!  colony-forming units (CFU)/ml in TSB. Serial two fold dilutions of gentamicin (ranging 
from 0.125 µg/ml to 64 µg/ml) were used. The MIC was defined as the lowest concentration 
of gentamicin that inhibits visible growth in a broth culture after 24 h (instead of 16 to 18 h, as 
recommended by CLSI). Tubes were incubated at 37 ºC for 24 h under static conditions. 
Control tubes contained no antibiotic. 
The MBC was described as the lowest concentration of gentamicin that results in ≥ 
99.9% killing of bacterial cells in the inoculum and was obtained by subculturing 100 µl 
suspension from each tube, in which the MIC assay showed no apparent growth, onto TSB 
agar plates. Agar plates were incubated for 24 h and 37 ºC and visually inspected. 
MIC and MBC values were determined in duplicate using separately grown bacteria. 
 
2.7.2. Biofilm susceptibility to gentamicin  
To test whether the approach caused increased antibiotic (in this case, gentamicin) 
susceptibility, two different strategies were used to treat biofilms grown on PLGA-DNase I and 
PLGA-inulin packaged DNase I coatings: 24 h of total biofilm growth, of which 9h without 
gentamicin and 15 h with gentamicin MIC; versus 48 h of total biofilm growth, of which 24 h 
without gentamicin and 24 h in the presence of the gentamicin MIC. Biofilm growth was 
initiated using the same experimental procedure as described before for both staphylococcal 
strains (section 2.4. and section 2.5.) (tetracycline was not added to the pre-cultures or when 
the medium was renewed).  
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After the incubation period, biofilm formation on the samples (titanium, PLGA-DNase I 
and PLGA-inulin packaged DNase I) was visualized by CLSM, after staining for 30 min in the 
dark at room temperature with a LIVE/DEAD BacLight Bacterial Viability Kit (Life 
Technologies®, GmbH, Darmstadt, Germany). The biovolumes of dead and live cells were 
determined as described before, using MATLAB.  
 
2.8. Statistics  
Statistical analysis was performed using Excel and Statistical Package for the Social 
Sciences ((SPSS), Inc., Chicago, IL) software version 22.0 for Mac. All experiments, except for 
the particle size determination by laser diffraction (section 2.2.1), degradation time of the 
coatings (section 2.2.4.) and experiments involving gentamicin (section 2.6.), were performed 
in triplicate, the data averaged and the standard deviations calculated. Bacterial adhesion, 
biofilm formation and mammalian cell adhesion data followed a normal distribution (Shapiro-
Wilk test, p<0.05). Statistical significance of differences between the several coatings studied 
was determined using a one-way Analysis of Variance (ANOVA) followed Tukey’s HSD post hoc 
test and a p-value of <0.05 was considered significant. 
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3.1. Particle preparation 
3.1.1. Particle dimension 
Spray-drying of inulin, DNase I or inulin DNase I mixtures, resulted in particles with a 
mean diameter of approximately 1 µm (Table 3.1 and Appendices – Figure A.3, Figure A.4 and 
Figure A.5). Inulin appeared to be partly crystallized (as indicated by the high x90 value), most 
likely due to wetting during storage. Nevertheless, particle size was consistent amongst the 
different constituents. 
 
Table 3.1. Geometric mean diameter (µm) of inulin, DNase I and inulin-DNase I (ratio 4:1) particles and SPAN 
values of dry powders ± standard deviations (SD) over two measurements calculated automatically by the 
laser diffraction software. SPAN is the width of distribution based on the x10, x50 and x90 quantile 
Particles x10 (µm) x50 (µm) x90 (µm) SPAN 
Inulin 0.62 ± 0.00 1.21 ± 0.01 106.25 ± 7.67 87.30 
DNase I  0.61 ± 0.00 1.11 ± 0.01 2.32 ± 0.06 1.54 
Inulin - DNase I  0.62 ± 0.00 1.16 ± 0.01 2.47 ± 0.02 1.59 
 
3.2. Surface coating  
3.2.1. Coating roughness and thickness 
The surface roughness of uncoated titanium substrata (Figure 3.1.A)) was 
approximately 0.58 ± 0.17 µm. Thickness of PLGA coatings increased when these contained 
particles of DNase I, doubling the total thickness of the coating when compared to sole PLGA. 
PLGA-Inulin and PLGA-DNase I (1/5) coatings presented higher values of Ra (Figure 
3.1.B,C,D,E,F), thus indicating a rougher surface (Table 3.2).  
 
Table 3.2. Average roughness (Ra) (µm) and thickness (µm) of the various coatings applied on the titanium 
surface. Values are expressed as means ± SD over three experiments with separately prepared coatings. 
*Indicates significant differences in Ra and thickness compared to the titanium surface coated with only 
PLGA (p<0.05) 
Coating Ra (μm) Thickness (μm) 
PLGA 1.88 ± 0.41 5.96 ± 1.29 
PLGA - Inulin  5.10 ± 0.80* 7.70 ± 2.50 
PLGA - DNase I 4.77 ± 1.87 10.59 ± 3.23* 
PLGA - DNase I (1/5) 7.23 ± 3.41* 11.95 ± 4.14* 
PLGA - Inulin - packaged DNase I 4.13 ± 1.22 10.11 ± 2.06* 
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Figure 3.1. Height map generated through white light interferometry in i) 2-Dimensional (2-D) and ii) 3-D for 
A) uncoated titanium surface; B) PLGA; C) PLGA-Inulin; D) PLGA-DNase I; E) PLGA-DNase (1/5); and F) PLGA-
inulin-packaged DNase I. Total area is 2 mm × 2 mm and colours are artificially generated to yield a height 
map.  
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3.2.2. Coating degradation 
Degradation times of the various coatings in PBS revealed that coatings containing 
DNase I particles exhibit a longer degradation time when compared to sole PLGA and PLGA-
inulin. Coatings without DNase I degraded within 40 d, while coatings containing DNase I were 
still present after 70 d (Table 3.3 and Figure 3.2). 
 
Table 3.3. Degradation time (d) in PBS solution of the various coatings applied on titanium surfaces 
Coating Degradation time (d) 
PLGA 38 
PLGA - inulin  40 
PLGA - DNase I 77 
PLGA - DNase I (1/5) 84 
PLGA - inulin packaged DNase I 105 
 
 
Figure 3.2. Pictures of the different PLGA coatings: i) PLGA; ii) PLGA-inulin; iii) PLGA-DNase I; iv) PLGA-DNase 
I (1/5); and v) PLGA-inulin packaged DNase I after A) 0 d, B) 14 d, C) 35 d and D) 56 d of immersion on a PBS 
solution. The red arrows point to some points of the surface where the coating is still present. 
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3.3. Release kinetics 
3.3.1. DNase I and inulin release kinetics 
PLGA-protected coatings containing only DNase I particles (PLGA-DNase I) or inulin-
packaged DNase I particles showed a burst release of DNase I (Figure 3.3.A)) or DNase I and 
inulin (Figure 3.4.A)), respectively, within the first h of exposure to PBS, after which the release 
continued at a slower rate. More accurately, approximately 47% and 40% of the total content of 
DNase I incorporated in the coatings of PLGA-DNase I (total DNase I contents was 1000 µg) 
and PLGA-inulin packaged DNase I (total DNase I content was 200 µg) were released in the 
first 1 h. Note that the ratio of inulin over DNase I released was 4:1 on average, in line with the 
ratio of inulin over DNase I incorporated during particle preparation (section 2.2.2.). When 
assuming that particles of DNase I or inulin-packaged DNase I retained in the corresponding 
PLGA coating do not suffer degradation, after 120 h coatings of PLGA-DNase I and PLGA-inulin 
packaged DNase I still contain around 22% and 10% respectively, of the initial amount of 
DNase I incorporated. 
Regarding the surface topography of the PLGA-DNase I and PLGA-inulin packaged 
DNase I coatings after immersion in PBS for 1 h and for 120 h, it was observed that the 
degradation transformed the coating from relatively smooth after 1 h in PBS to a surface 
covered with holes after 120 h in PBS. The observed holes in the coatings of PLGA-DNase I 
(Figure 3.3.B)) and PLGA-inulin packaged DNase I (Figure 3.4.B)) were caused by the release 
of the DNase I and DNase I-inulin particles, respectively. 
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Figure 3.3. Release of DNase I from PLGA-DNase I. A) Cumulative amounts of DNase I released (µg) from 
PLGA-DNase I immersed in PBS for different periods of time (h) obtained specphotometrically, using the 
calibration curve presented in Figure B.1. Error bars indicate SD over three experiments with separately 
prepared coatings. B) SEM images of the PLGA-DNase I coating after immersion in PBS for i) 1 h (scale bar 
represents 604 µm) and ii) 120 h (scale bar represents 566 µm). 
 
 
 
Figure 3.4. Release of DNase I and inulin from PLGA-inulin packaged DNase I. A) Cumulative amounts of 
DNase I and inulin released (µg) from PLGA-inulin-packaged DNase I immersed in PBS for different periods of 
time (h) obtained spectrophotometrically, using the calibration curve presented in Figure B.2. Error bars 
indicate SD over three experiments with separately prepared coatings. B) SEM images of the PLGA-inulin 
packaged DNase I coating after immersion in PBS during i) 1 h (scale bar represents 133 µm) and ii) 120 h 
(scale bar represents 156 µm). 
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3.3.2. Initial burst release 
In order to prevent the initial burst release of DNase I, an extra layer of PLGA was 
added on top of the previously described coatings or, in another approach, the thickness of the 
PLGA layer for PLGA-DNase I and PLGA-Inulin-packaged DNase I coatings was increased. Both 
methods were effective in the case of PLGA-DNase I, reducing the initial release of DNase I by 
90% and 70% in the first h (Figure 3.5.A). However, for the PLGA-Inulin-packaged DNase I 
coating, the deposition of an extra PLGA layer decreased the amount of DNase I released 
within four hours, while increasing the thickness of the coating did not significantly change the 
release kinetics (Figure 3.5.B). 
 
 
 
 
Figure 3.5. Cumulative amount of DNase I released (µg) from A) PLGA-DNase I and B) PLGA-Inulin-packaged 
DNase I (after immersion in PBS for 1 h, 4 h and 8 h) coatings with an extra layer of PLGA on the top of the 
first coating or after increasing the thickness of the PLGA layer. The values were obtained 
spectrophotometrically using the calibration curve for DNase I (Figure B.1). Error bars indicate SD over three 
experiments with separately prepared coatings. *Indicate significant differences in the amount of DNase I 
released when compared to the quantity of DNase I released in the release kinetics (Figure 3.3.A) for the 
PLGA-DNase I coating or Figure 3.4.A) for the PLGA-Inulin-packaged DNase I coating) at the same time point 
(p<0.05). 
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3.4. Initial bacterial adhesion and biofilm growth 
3.4.1. Initial bacterial adhesion  
Fluorescence microscopy images indicated that bacterial adhesion was greatly reduced 
by the release of DNase I from PLGA coatings for both S. aureus 12600GFP (Figure 3.6.A)) and 
S. aureus Newman D2CGFP (Figure 3.6.B)).  
The number of initially adhering staphylococci on titanium substrata was not affected 
by applying a coating consisting of only PLGA, or PLGA containing inulin particles. Addition of 
particles containing DNase I to the PLGA coating significantly reduced staphylococcal 
adhesion, regardless of whether particles consisted of only DNase I (PLGA-DNase I and PLGA-
DNase I (1/5)) or inulin-packaged DNase I (PLGA-inulin packaged DNase I) (Figure 3.7). Note 
that bacterial adhesion is considered the first step in biofilm formation, therefore it is believed 
to be one of the most important targets to prevent the development of bacterial biofilms. 
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Figure 3.6. Fluorescence microscopy images of A) S. aureus ATCC 12600GFP and B) S. aureus Newman D2CGFP 
adhesion after 1 h in PBS to i) titanium surfaces and the various coatings: ii) PLGA; iii) PLGA-inulin; iv) PLGA-
DNase I; v) PLGA-DNase I (1/5); and vi) PLGA-inulin-packaged DNase I. Scale bar denotes 100 µm. 
 
 
Figure 3.7. Number of adhering S. aureus ATCC 12600GFP and S. aureus Newman D2CGFP (x 106 cm-2) after 1 h 
adhesion in PBS to titanium surfaces and the various coatings. Error bars represent the SD over three 
experiments with separately grown bacteria. *Indicates significant differences in the numbers of adhering 
bacteria, within the same strain, compared to titanium and coatings not containing DNase I (p<0.05). 
 
Results 
Chapter 3 | 58 
 
3.4.2. Biofilm growth  
CLSM 3-D reconstructed images of staphylococcal biofilms grown for 24 h (Figure 
3.8.A) and Figure 3.9.A)), show abundant biofilm formation on bare titanium and coatings 
without DNase I particles, while the presence of DNase I particles in coatings keeps biofilm 
formation limited. In fact, the biovolume of both S. aureus ATCC 12600GFP and S. aureus 
Newman D2CGFP biofilms significantly decreased for the PLGA-DNase I and PLGA-Inulin 
packaged DNase I when compared with the biovolume for titanium and PLGA coatings without 
DNase I particles (Figure 3.10.A)). Increasing the growth time of biofilms to 72 h (Figure 
3.8.B), Figure 3.9.B) and Figure 3.10.B)) and 120 h (Figure 3.8.C) and Figure 3.9.C) and 
Figure 3.10.C)) showed the same abundant biofilm formation on coated surfaces lacking 
DNase I, whereas coatings containing DNase I and inulin-packaged DNase I remained able to 
inhibit biofilm formation. However, an increase in biofilm formation over this time periods was 
observed for coatings containing only one-fifth of the DNase I.  
The inulin-packaging of DNase I yielded much stronger reductions in biovolume for 
both staphylococcus strains, indicating that DNase I activity is better preserved by inulin-
packaging than by exclusively protecting it in PLGA. This effect is amplified by the amount of 
DNase I being five-fold lower in inulin-packaged DNase I coatings, compared to PLGA-DNase I 
coating, due to the absence of inulin. In fact, as mentioned, the PLGA coating with the same 
amount of DNase I as the quantity present in the coating of PLGA-inulin packaging DNase I, 
the PLGA-DNase I (1/5) coating loses effectiveness over time, i.e. there is an increase in the 
biovolume in both S. aureus ATCC 12600GFP and S. aureus Newman D2CGFP. 
Non-fluorescence-based OCT (Figure 3.11) images of staphylococcal biofilms grown for 
72 h confirmed the results obtained by CLSM. Abundant biofilm formation was visible on bare 
titanium uncoated and coatings with only PLGA, PLGA inulin particles and coatings with a 
concentration of DNase I particles five times lower than the other coating with only DNase I 
particles. Biofilm formation is nearly absent on PLGA-DNase I and PLGA-inulin-packaged DNase 
I coatings. 
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Figure 3.8. Confocal Laser Scanning Microscopy (CLSM) 3-D images of A) 24 h, B) 72 h and C) 120 h old 
biofilms of S. aureus ATCC 12600GFP on i) titanium surfaces and various coatings: ii) PLGA; iii) PLGA-inulin; iv) 
PLGA-DNase I; v) PLGA-DNase I (1/5) and vi) PLGA-inulin-packaged DNase I. The base of the biofilm is 375 x 
375 µm. 
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Figure 3.9. Confocal Laser Scanning Microscopy (CLSM) 3-D images of A) 24 h, B) 72 h and C) 120 h old 
biofilms of S. aureus Newman D2CGFP on i) titanium surfaces and various coatings: ii) PLGA; iii) PLGA-inulin; iv) 
PLGA-DNase I; v) PLGA-DNase I (1/5) and vi) PLGA-inulin-packaged DNase I. The base of the biofilm is 375 x 
375 µm. 
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Figure 3.10. Average biovolumes (µm3 µm-2) of A) 24 h, B) 72 h and C) 120 h old biofilms of S. aureus ATCC 
12600GFP and S. aureus Newman D2CGFP grown in TSB on titanium surfaces and on the various coatings. Error 
bars represent SD over three experiments with separately grown bacteria and different batches of coated 
samples. *, # and τ indicate significant differences in the biovolumes, within the same strain, compared to 
titanium, PLGA and PLGA-Inulin, respectively (p<0.05). 
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Figure 3.11. In-situ optical coherence tomography (OCT) observations of biofilm formation. 3-D (top) (scale 
bar represents 1 mm) and side (bottom) (scale bar represents 10 µm) views of A) S. aureus ATCC 12600GF 
and B) S. aureus Newman D2CGF biofilms 72 h old obtained using non-fluorescence-based, optical coherence 
tomography on i) titanium surfaces and various coatings: ii) PLGA; iii) PLGA-inulin; iv) PLGA-DNase I; v) PLGA-
DNase I (1/5) and vi) PLGA-inulin-packaged DNase I.  
 
3.5. XTT assay and cell adhesion assay using U-2 OS 
3.5.1. XTT assay 
Cells growing on top of PLGA coatings and on the surface of the wells surrounding 
each titanium substrata showed similar metabolic activity when compared to cells in the 
presence of bare titanium. Additionally, no significant differences between the metabolic 
activity of U-2 OS cells in the well and cells in the material, i.e. coated substrata, were 
observed (Figure 3.12). 
 
 
Figure 3.12. Metabolic activity of the U-2 OS cells (%) in each coated substrata (material) and on the 
surrounding substrata (well) compared to the U-2 OS cell in the same conditions but in the presence of 
titanium (dashed line). Error bars represent SD over three experiments with separately grown U-2 OS cells 
and different batches of coated samples.  
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3.5.2. Cell adhesion assay  
Besides the influence on metabolic activity, coatings were assessed for their influence 
on the adhesion and proliferation of human osteosarcoma U-2 OS cells. None of the coatings 
showed a negative effect on the adhesion and proliferation of U-2 OS cells after 24 h of 
incubation. Cells adhered to all substrata and formed a confluent layer within 24 h (Figure 
3.13). Additionally, no significant differences in the number of adhering cells were observed 
between any of the coatings and the titanium, and between the coatings and the wells in which 
incubation of the cells was performed (Figure 3.14). 
 
 
Figure 3.13. Confocal Laser Scanning Microscopy (CLSM) images of adhering U-2 OS cells after 24 h of 
growth on A) each one of the substrata: i) titanium surfaces; ii) PLGA; iii) PLGA-inulin; iv) PLGA-DNase I; v) 
PLGA-DNase I (1/5); and vi) PLGA-inulin-packaged DNase I and B) the surface of the well surrounding each 
one of the substrata mentioned. Scale bar denotes 100 µm. 
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Figure 3.14. Number of adhering U-2 OS cells (x 104 cm-2) after 24 h of growth on titanium surfaces and the 
various coatings and the surface of the well surrounding each one of the substrata. Error bars represent SD 
over three experiments with separately grown U-2 OS cells and different batches of coated samples.  
 
3.6. Pilot experiment: effect of gentamicin when 
combined with the PLGA coatings containing either DNase I 
or inulin-packaged DNase I  
3.6.1. Minimum inhibitory concentration and minimum 
bactericidal concentration 
In order to determine the susceptibility of planktonic staphylococci to gentamicin, the 
MIC and MBC for both S. aureus ATCC 12600GFP and S. aureus Newman D2CGFP were 
determined by macrodilution (Table 3.4). To evaluate the influence of PLGA-DNase I and PLGA-
inulin packaged DNase I coatings (chosen by their efficacy in preventing the biofilm formation 
(section 3.4.2.)) on the susceptibility to gentamicin by both staphylococcal strains, 8 µg/ml of 
gentamicin, a concentration between the MIC and the MBC, was used to treat mature biofilms. 
 
Table 3.4. MIC (µg/ml) and MBC (µg/ml) of gentamicin for the S. aureus strains studied 
S. aureus strain MIC (µg/ml) MBC (µg/ml) 
ATCC 12600GFP >  4 <  8 >  8 <  16 
Newman D2CGFP  >  4 <  8 >  8 <  16 
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3.6.2. Biofilm susceptibility to gentamicin 
 For 24 h (15 h in the presence of gentamicin) and 48 h (24 h in the presence of 
gentamicin) of biofilm growth, coatings of PLGA-DNase I and PLGA-Inulin packaged DNase I 
increased the susceptibility of both staphylococcal strains studied (Figure 3.15 and Figure 
3.17). This effect seemed to be higher for the PLGA-DNase I coating (Figure 3.16 and Figure 
3.18). In addition, for the uncoated titanium the ratio biovolume live bacteria/biovolume dead 
bacteria is above 1, meaning more live than dead cells; which did not occur for the PLGA 
coatings in almost all the situations.  
 
 
Figure 3.15. Confocal Laser Scanning Microscopy (CLSM) overlay images for 24 h old biofilm (9 h of biofilm 
growth without gentamicin and 15 h of biofilm growth in the presence of 8 µg/ml gentamicin) of A) S. aureus 
ATCC 12600GFP and B) S. aureus Newman D2CGFP for i) titanium; ii) PLGA-DNase I; and iii) PLGA-Inulin-
packaged DNase I. Living cells fluoresced green and dead cells appeared red. Scale bar represents 100 µm. 
 
 
Figure 3.16. Biovolume live bacteria/biovolume dead bacteria for 24 h old biofilm (9 h of biofilm growth 
without gentamicin and 15 h of biofilm growth in the presence of 8 µg/ml gentamicin) for titanium, PLGA-
DNase I, and PLGA-Inulin-packaged DNase I.  
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Figure 3.17. Confocal Laser Scanning Microscopy (CLSM) overlay images for 48 h old biofilm (24 h of biofilm 
growth without gentamicin and 24 h of biofilm growth in the presence of 8 µg/ml gentamicin) of A) S. aureus 
ATCC 12600GFP and B) S. aureus Newman D2CGFP for i) titanium; ii) PLGA-DNase I; and iii) PLGA-Inulin-
packaged DNase I. Living cells fluoresced green and dead cells appeared red. Scale bar represents 100 µm. 
 
 
Figure 3.18. Biovolume live bacteria/biovolume dead bacteria for 48 h old biofilm (24 h of biofilm growth 
without gentamicin and 24 h of biofilm growth in the presence of 8 µg/ml gentamicin) for titanium, PLGA-
DNase I, and PLGA-Inulin-packaged DNase I. 
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4.1. Particle preparation 
4.1.1. Particle dimension 
Frequently, the methods used to obtain proteins in the dry state from a solution are 
spray-drying and freeze-drying [99]. Spray-drying of inulin, DNase I or inulin-packaged DNase I, 
resulted in particles with a very similar size (mean diameter around 1 µm) (Table 3.1). The 
polydispersity, i.e. the width of the particle size distribution, of the powder was measured by 
the SPAN (SPAN=(particle diameter at 90% cumulative size) – (particle diameter at 10% 
cumulative size)/(particle diameter at 50% cumulative size)). A small SPAN, as observed for 
DNase I and inulin-DNase I particles, indicates a narrow size distribution [100].  
Inulin DP23 formulations were successfully spray-dried, showing no coalescence 
during spray-drying and subsequent storage at ambient conditions [87,88]. However, the inulin 
appeared to have partly crystallized (as indicated by the high x90 value – Table 3.1), which is 
most often due to wetting during storage. Consequently, at the normal laser diffraction 
conditions, some of the agglomerated particles were not broken up by the air. This does not 
mean that the inulin particles will not break up when dispersed in PLGA, but it is an indication 
that agglomerates might be present.  
Drying of pure proteins or enzymes often leads to partial or total inactivation due to 
damages in the tertiary structure (vital to their function and that can be affected by numerous 
physical – like denaturation – and chemical – such as hydrolysis – degradation mechanisms, 
that can eventually lead to a non-functional protein [99]). To withstand the degradation during 
processing and storage, stabilizing excipients such as mannitol, sucrose, trehalose and inulin 
are frequently used. Inulin is a sugar which helps to prevent damage of the tertiary structure of 
enzymes and has been used in the encapsulation of DNase I towards its use for cystic fibrosis 
treatment. More than 80% of the activity of DNase can be preserved during weeks of storage 
even at 85 °C by spray-drying this substance with inulin [12,87,88]. According to Swartjes and 
co-workers [12], this is essential to assure that the activity of DNase I does not get lost during 
the implantation of a coated biomaterial. 
The preference for the ratio 1:4 of DNase I particles encapsulated in inulin was the 
result of a balance between having a high enough amount of DNase I to observe the 
effectiveness of the PLGA coatings (to prevent initial bacterial adhesion and biofilm formation 
for both studied staphylococcal strains) and, simultaneously, guarantee the stability of DNase I.  
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DNase I is considered a very stable protein, however, inulin protects DNase I during coating 
preparation since a major issue hindering the evolution of PLGA as protein drug carrier is 
protein stability. The organic solvents used (PLGA needs to be dissolved in a volatile solvent – 
such as acetonitrile) and the acidic microenvironment generated during polymer degradation 
are factors that most negatively affect the activity of DNase I [12,101].  
 
4.2. Surface coating  
4.2.1. Roughness and thickness of the coatings 
A surface can be seen as a succession of peaks and valleys with several heights and 
spacings in a plane. The roughness parameter most frequently studied is the Ra (universally 
recognized and most used international parameter of roughness [102]), which describes the 
typical height variation of the surface [103], and can be measured using several equipments 
such as light interferometers, CLSM and atomic force microscopy (AFM). Using white light 
interferometry, it was concluded that the PLGA coatings displayed different roughness values, 
even though none of them could be considered as rough (Table 3.2). Biomedical devices 
usually present a smooth surface due to the commonly accepted perception that a smoother 
surface lowers the probability of bacterial adhesion, although some studies have suggested 
otherwise (it is believed that bacterial adhesion is enhanced when the features of the surface 
have dimensions or spacings similar to the bacterial size) [103]. The elevated Ra value of 
PLGA-inulin and PLGA-DNase I coatings is explained by the formation of small aggregates 
during application of the PLGA.  
When the cut was made in the PLGA coatings (to measure the thickness), exposing the 
titanium surface, some parts of the coating were deposited on both sides resulting in peaks. 
This debris is perfectly visible in the 3-D pictures (Figure 3.1). The small thickness measured 
for the various PLGA coatings permit the exploitation of controlled release without substantial 
variations of the mechanical properties of the substrate material [104]. The thickness of PLGA 
coatings increased by the presence of particles doubling the total thickness of the coating 
when compared to only PLGA, however coating thickness was still under 15 µm (more 
precisely between 6 µm and 12 µm) (Table 3.2), which it was assumed as still sufficiently thin 
to not alter the mechanical properties of the material, thus allowing the performance of the 
function for which it was developed. 
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4.2.2. Degradation of the coatings 
The variety of implants applied in the clinical setting demands the design of any future 
antimicrobial coating to be prudently matched to the intended application. Thereby, during the 
design process a number of variables must be considered, such as the duration of the coating 
efficacy (whether to apply in a short term implant or in a long term implant) and whether the 
mechanism applied should release antimicrobials (kills both microorganisms associated with 
the implant surface directly and susceptible pathogens in the surrounding area) or present the 
active component bound to the surface (the release of drug is easier to control) [105].  
The PLGA coatings studied in this thesis were designed to prevent the initial bacterial 
adhesion and biofilm formation in orthopaedics implants, i.e. permanent implants. Therefore, 
the degradation rate of the coatings should be slow in order to prevent the occurrence of 
infections in the longest possible period of time. The degradation times of the various coatings 
in PBS revealed a longer degradation time for coatings containing DNase I particles, when 
compared to PLGA only and PLGA-inulin. In fact, coatings not containing DNase I degraded 
within 40 d, while remains of coatings containing DNase I were still present after 60 d (Table 
3.3). The efficiency of the PLGA coatings has not been studied for such long periods of time 
(only for a maximum of 5 d), but their presence on the titanium surface is a good indication 
that they may help to combat the BAI when combined with antibiotics. Furthermore, over time, 
the probability of BAI decreases, since the human body considers the implant of a foreign body 
and forms a protective capsule of fibrous tissue around it. 
According to Daghighi et al. [14], the use of degradable biomaterials (instead of non-
degradable biomaterials) is an efficient strategy to reduce the risk of infection. In fact, these 
biomaterials are less susceptible to the occurrence of infections due to the release of anti-
bacterial peptides, augmented vascularization (aids the access of immune cells to injured and 
infected host tissue), diminution of the local immune responses (non-degradable materials may 
constantly attract the attention of the immune system, leading to frustrated reactions – 
biodegradable materials allow the restoration of the immune system after full degradation), and 
also the reduction of available area of the surface for bacterial colonization during the 
degradation process. In this context, the combination of a non-degradable material (titanium 
implant) with a biodegradable coating (PLGA coating containing DNase I particles) with a long 
degradation time could be favorable, mitigating the probability of BAI.  
Discussion 
 74 | Chapter 4 
 
4.3. Release kinetics 
4.3.1. DNase I and inulin release kinetics 
The release profiles of coatings containing antimicrobial compounds are often difficult 
to effectively control and inappropriate concentrations of antimicrobials can be released. For 
many of these coatings, an “initial burst” of drug release occurs, during which a significant 
amount of the drug is released through the early stage of the release process. This initial 
period of high release is typically followed by a longer period of diminishing release [105]. 
PLGA-DNase I and PLGA-inulin packaged DNase I coatings showed an initial burst 
release during the first h of placement in PBS, releasing almost 47% (Figure 3.3.A)) and 40% 
(Figure 3.4.A)) of the total amount of DNase I. The initial burst release can be attributed to 
particles within the top layer of PLGA (Figure 4.1.A)). The presence of particles at the interface 
of the coating leads to two events contributing to the high initial release. First, upon immersion 
of coated material in PBS, particles which are in direct contact with the outside environment 
start to dissolve and are released. Second, the release of particles directly at the interface 
leads to a porous outer layer through which liquid can reach other particles more quickly, 
leading to release of particles that were connected to the earliest dissolved particles (Figure 
4.1.B)). Thus, when in contact with a PBS solution, these particles are the first to be released 
(unlike those particles that are in the deeper layers of polymer), causing the initial burst 
release. It appears that within 1 h all the particles captured in the top layer are dissolved, since 
after this first h the release of DNase I continued at a slower rate. After this initial phase, a 
diffusion-controlled release phase could be observed, which is attributed to pore-diffusion of 
protein. In fact, after 4 h and 120 h immersion in PBS the release of DNase I was 
approximately and 11.1% and 0.4% for the PLGA-DNase I coatings and 6.8% (for both time 
points) for the PLGA-inulin packaged DNase I. The protein that has been entrapped inside of 
the polymer matrix might be released in a phase controlled by polymer erosion [106]. It is 
throughout this latter phase that bacteria may be exposed to sub-inhibitory concentrations of 
antimicrobials which is favourable to the development of resistance, and therefore may reduce 
efficiency of the treatment [105]. However, resistance against enzymatic treatment has never 
been reported [12], hence it is not expected any efficiency reduction of the coatings due to the 
development of bacterial resistance because of the presence of a reduced amount of DNase I. 
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Figure 4.1. Schematic illustration of the process that led to the initial burst release of DNase I particles: A) 
after deposition of the coating on the titanium surface; B) after 1 h immersion in PBS. The same happens for 
the PLGA-inulin packaged DNase I coating. 
 
Regarding the surface topography of the PLGA-DNase I and PLGA-inulin packaged 
DNase I coatings after immersion in PBS for 1 h and 120 h, it was found that degradation 
transformed the coating from relatively smooth and non-porous after 1 h in PBS to a surface 
covered with holes after 120 h in PBS. It can be speculated that the increased porosity of the 
coatings of PLGA-DNase I (Figure 3.3.B)) and PLGA-inulin packaged DNase I (Figure 3.4.B)) is 
attributed to the voids left behind by the released of DNase I and DNase I-inulin particles, 
respectively. Although the time points between 1 h and 120 h were not observed using SEM, it 
was expected that the PLGA surface for both coatings exhibited an incrementally porous 
surface. The formation of these pores offers transport pathway to the drug and facilitates its 
diffusion through the polymeric coating [107]. After 120 h immersion in PBS, the holes 
presented in the PLGA-DNase I coating presented a circular shape (allows a more precise 
control of the DNase I release over porosity), unlike the holes in the PLGA-inulin packaged 
DNase I coating. Conceivably, the presence of DNase I inside the inulin particles changes their 
shape to a bumpier one. Deposition of artefacts on the PLGA-DNase I coating, probably during 
its preparation, resulted in the appearance of fibers on the coating surface (Figure 3.3.B.i)). 
However, it is improbable that this affected the release of protein from the coating, as it most 
likely originated from SEM preparation procedures.  
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4.3.2. Prevention of the initial burst release 
PLGA is a synthetic biodegradable and biocompatible copolymer, and also FDA 
approved for biomedical applications, including implantation [12]. PLGA is being increasingly 
used in sustained drug delivery applications [104] since the drug release can be achieved by 
different approaches [101]. Altogether, this makes PLGA an ideal candidate to protect DNase I 
on implant materials in order to prevent bacterial adhesion and biofilm formation, with the 
possibility to fine-tune its release [12]. There are three direct possibilities to adjust the 
degradation of, and consequently alter the release. To prevent, or lower, the initial burst 
release of DNase I, one can increase the coating thickness (while maintaining the same 
amount of enzyme), increase the polymer molecular weight (leading to slower degradation 
[108]), or finally, vary the ratio of poly(lactic) acid (PLA) to poly(glycolic) acid (PGA) (PLA is 
more hydrophobic than PGA and, therefore, lactide-rich PLGA copolymers are less hydrophilic, 
absorb less water, and consequently, degrade more slowly [109]).  
Since the suspected cause of the initial burst release of DNase I was not directly 
related with the degradation of the copolymer, but with the deposition of particles on its 
surface, the options of using PLGA with a higher molecular weight or using higher amounts of 
PLA were discarded. Instead, a direct and an indirect method to increase the PLGA coating 
thickness were used. By either directly increasing the PLGA content, or by placing an extra 
layer of PLGA on the top of the regular coating, the coating thickness increased and it was 
hypothesized that less particles would be present at the coating interface. 
The two implemented strategies to prevent the initial burst of DNase I showed to be 
more efficient for the PLGA-DNase I than for PLGA-inulin packaged DNase I coating. In the 
case of the PLGA-inulin packaged DNase I coating only the deposition of the additional layer of 
PLGA coating decreased the amount of DNase I released significantly at 4 h (Figure 3.5.B)). 
Regarding the PLGA-DNase I coating, the deposition of an extra layer of PLGA decreased the 
amount of DNase I released by 90%, 80% and 78% at 1 h, 4 h and 8 h, respectively (Figure 
3.5.A)). This method prevents the direct contact between the DNase I particles deposited at 
the surface of the polymer layers and the external environment by the additionally applied 
PLGA layer. Accordingly, a large portion of the release of DNase I particles into the 
surroundings is only achievable after degradation (complete or partial) of the extra PLGA layer. 
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In turn, the increase of the PLGA layer thickness provided a decrease of 71% and 65% (for 4 h 
and 8 h) of the amount of enzyme released for the three earliest time points (Figure 3.5.A)). 
Even though the initial release decreased, some of the DNase I particles were still at the 
interface of the PLGA surface in contact with the aqueous environment, explaining the 
differences compared to the previous approach. Numerically analyzing, the most efficient 
strategy was the deposition of a PLGA extra layer; however, in practical terms a slightly higher 
release of DNase I in the first few hours might be preferable, since in this period of time the 
probability of occurrence of BAI is higher (the patient is more susceptible).  
It was intended to avoid the initial burst release of DNase I, in order to prolong the 
period of time during which the coatings are effective, i.e. to optimize the coatings efficiency. In 
fact, the presence of the PLGA extra layer allows the release of the same amount of DNase I at 
a slower rate. The regular release of DNase I from the PLGA coating combined with an 
appropriate antibiotic therapy might reduce the risk of infection to satisfactory levels for a 
suitable period of time. 
Finally, it is important to emphasize that the initial burst release is a problem, 
especially for highly potent drugs, since it increases the risk of serious side effects in vivo 
[106]. However, DNase I is naturally produced in the human body by the pancreas, kidneys, 
liver and subsequently released into body fluids, being aware of any negative effects caused by 
this enzyme to humans. Evidently, the absence of negative effects is considered a critical point 
for the further downstream translation of the DNase I coating to clinical application [58,110].  
 
4.4. Initial bacterial adhesion and biofilm growth 
The increasing understanding of how biofilms form and the role of different 
components involved in cell adhesion is providing valuable information for the development of 
complete new strategies to combat bactericidal colonization in unwanted situations [71]. 
According to Meng Chen and co-workers [70], the most promising methodologies currently 
being developed to prevent and treat infections caused by biofilms include of small molecules 
and matrix-targeting enzymes to inhibit or disrupt the process of biofilm formation and 
proliferation. The resulting anti-biofilm coatings that will be used to modify the surface of 
medical devices will lead to implants that are highly resistant to biofilm formation. These novel 
anti-biofilm tools could eventually lead to anti-biofilm treatments that are superior to the current 
antibiotic therapy.  
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Since eDNA is ubiquitous and pivotal in bacterial adhesion and biofilm formation, 
attacking this essential component of the EPS matrix by DNase I, has been considered a 
possible approach to prevent biofilm formation [58,59]. Therefore, this dissertation focused on 
studying of a protective biodegradable PLGA coating on titanium in which DNase I is embedded 
with the proposal of preventing initial bacterial adhesion and biofilm formation.  
Destabilization of biofilms by removing eDNA has been documented by the addition of 
DNase during or after biofilm formation [59]. In this thesis, DNase I was present in the PLGA 
coatings, being in contact with each one of the staphylococcal strains since de initial bacterial 
adhesion. 
All coatings with DNase I particles (PLGA-DNase I, PLGA-DNase I (1/5) and PLGA-
inulin packaged DNase I) were efficient in the prevention of initial bacterial adhesion by both 
staphylococcal strains, while all controls without DNase I showed high numbers of bacteria 
adhered to the surface (Figure 3.6 and 3.7).  
Analyzing the results for 24 h of biofilm formation, it may be concluded that, the 
outcome is similar to the obtained for the initial bacterial adhesion except for the biovolume of 
S. aureus Newman D2CGFP on PLGA-DNase I (1/5) coatings which is not significantly different 
from the biovolume in the PLGA-inulin (Figure 3.8.A), Figure 3.9.A) and Figure 3.10.A)). 
Paralleling the biovolumes achieved in this work for 24 h incubation with the ones presented 
by Swartjes and co-workers for 20 h [12], it is reasonable to justify that the disparities are 
caused by the presence of tetracycline in the TSB medium used in the current study. Exposure 
of bacterial cells to this antibiotic (responsible for the selection of fluorescent cells) could have 
contributed to the lower levels of biovolumes acquired. Comparing with the previous referred 
study, in this work the biovolume was reduced to about 2 times for both staphylococcal strains 
on the titanium, PLGA and PLGA-inulin; and approximately 9 and 6 times for S. aureus ATCC 
12600GFP and 2 times for S. aureus Newman D2CGFP for the coatings PLGA-DNase I and PLGA-
inulin packaged DNase, respectively. Over time, the GFP plasmid (responsible for the bacterial 
fluorescence) within the bacterial strains disappears in the absence of the tetracycline in the 
medium, not being possible to observe the staphylococcal strains on the CLSM without any 
staining. However, the PLGA coatings studied are very reactive with the common stains (live 
and dead stains), impeding the clear visualization of the bacteria. In this sense, the tetracycline 
has been regularly added to the medium, guaranteeing that the bacteria with the GFP plasmid 
were being constantly selected and, subsequently visualized. 
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Regarding the results of 72 h of staphylococcal biofilm formation, the coating PLGA-
DNase I (1/5) only showed efficiency in the biovolume reduction when compared to titanium 
and exclusively for S. aureus ATCC 12600GFP. The scenario also changed for PLGA-DNase I and 
PLGA-inulin packaged DNase I, which were not able to significantly prevent biofilm formation of 
S. aureus ATCC 12600GFP on their surfaces with respect to only PLGA coating (Figure 3.8.B), 
Figure 3.9.B) and Figure 3.10.B)). Biofilms are complex and highly dynamic structures. 
Consequently, when working with biofilms, there is an elevated grade of unpredictability 
associated. It is possible to attempt to reduce the uncertainty (for instance, performing three 
completely independent experiments and in each one of them choose randomly three different 
spots to calculate the biovolume as in this study); although, there are factors that the operator 
cannot control. The fluctuation in the biovolume values obtained for the PLGA coating is one of 
those cases.  
Lastly, after 120 h of biofilm formation it is possible to conclude that both PLGA-DNase 
I and PLGA-inulin packaged DNase I coatings were competent in biofilm prevention when 
compared to titanium, but not when paralleled with the other controls, mainly with PLGA-inulin. 
In addition, PLGA-DNase I (1/5) was the less effective coating, not preventing the formation of 
biofilms not even when compared with titanium uncoated for S. aureus ATCC 12600GFP (Figure 
3.8.C), Figure 3.9.C) and Figure 3.10.C)). 
For the initial adhesion, comparing the number of adhered cells to the titanium and to 
each one of the coatings containing DNase I particles, this parameter was reduced by 
approximately 50 times in the surface of PLGA-DNase I and PLGA-DNase I (1/5) and over 100 
times in the surface of PLGA-inulin packaged DNase I coating, for both staphylococcal strains. 
Regarding the biofilm growth, comparing the biovolumes of both S. aureus strains biofilms 24 
h, 72 h and 120 h old with the biovolumes obtained on the titanium, a substantial reduction on 
the surfaces with the PLGA coatings comprising DNase I particles occurred. The biovolumes 
showed more marked differences for the S. aureus ATTCC 12600GFP and for the PLGA-inulin 
packaged DNase I coating. As a corollary, similarly to previous reported studies, packaging 
DNase I particles in inulin protects them during the coating process, as well as it aids 
increasing their shelf-life [12], since the coating PLGA-inulin packaged DNase I presents most 
of the times better (or at least equal) efficiency than the coating with five times more DNase I 
particles, PLGA-DNase I; and, also, exhibited for all the situations better efficacy than the 
coating with the same amount of DNase I, PLGA-DNase I (1/5). 
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In modern medicine, the combination of systemic antibiotic administration and local-
antibiotic delivery materials is used to combat perioperative infections. Local antibiotic delivery 
materials, such as gentamicin-loaded bone cements used in orthopedics for the fixation of hip 
and knee prostheses, are only active for a maximum of 24 h [58]. The first functional DNase I 
coating led to a delayed biofilm formation of up to 14, which is probable enough to mitigate the 
risk of acute infections related with medical implants [58,59]. In this work, the coatings PLGA-
DNase I and PLGA-inulin packaged DNase I possess antimicrobial activity for, at least, 120 h of 
growth for both studied S. aureus. It is expected that a timescale of 120 h is sufficiently long to 
prevent infections arising from bacteria introduced during the preoperative stage as it is 
currently done with a dose of postoperatively administered antibiotics [12].  
To exclude the possibility that the presence of DNase I in the coatings was hindering 
the visualization of the biofilm formed by S. aureus strains, biofilms of 72 h old were analyzed 
by OCT. OCT is a non-invasive optical tomography technique, which is increasingly used in 
medical diagnostics, since it is able to expose spatially resolved structural information on 
biofilm without any staining [111]. The results from OCT are qualitative and clearly in 
accordance with those obtained by CLSM, coating of PLGA-DNase I and PLGA-inulin packaged 
DNase I effectively decreases biofilm formation for up to 120 h for both S. aureus ATTCC 
12600GFP and S. aureus Newman D2CGFP (Figure 3.11).  
DNase I treatment has been used to decrease sputum viscosity (enabling better 
sputum clearance and reducing the risk of recurrent infections) in cystic fibrosis patients, and 
modern antibiotic treatment of biofilms in the lungs of cystic fibrosis patients is supplemented 
with rhDNase I [57-59,112]. DNase-mediated biofilm dispersal is also relevant for treating or 
preventing other types of biofilm infections, such as endocarditis or implant-associated 
infections. DNase treatment is an emergent therapy for bacterial vaginosis, a highly prevalent 
disorder of the vaginal microbiota for which antimicrobial treatment has a high rate of failure 
[59,113]. DNase may also be effective for other biomedical applications such as design of 
DNase I based wound care gels [57], as well as non-biomedical related applications including 
cleaning of food contact surfaces, wastewater treatment, seawater desalination or decreasing 
membrane biofouling systems employed in drinking water production, since controls the 
microbial attachment [54,59,114]. Obviously, the procedure that DNase treatment takes, 
whether a prophylactic surface coating, aerosolized mist, or a solution, must be adapted to the 
particular purpose [59].  
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A common limitation associated with the application of coatings on orthopedic 
implants is their fragility [115]. The conditions under which an orthopedic implant is inserted 
will inevitably lead to mechanical stress (causing metal scraping and consequently damaging 
the coating, exposing the metal surface to bacterial cells) and exposure to fluids, such as PBS 
or blood [12,115]. According to Swartjes and co-workers [12], the hardened PLGA provides 
protection against storage and handling conditions. Importantly, even in circumstances that 
can compromise the integrity of the PLGA coating (such as tight bone junctions), this coating 
remains in the place where it was applied, ensuring the protection of the implant. 
Although promising, the use of DNase I to prevent biofilm formation and initial 
bacterial adhesion has some limitations such as the absence of eDNA in certain bacterial 
biofilms [59]. The variation between matrices of different species (and even strains) makes it 
impossible to find a unifying element to be targeted for biofilm control [34]. Some bacterial 
species appear to have little or no dependence on eDNA and, in rare cases, eDNA can even 
act as a barrier to microbial adhesion [54]. In this context, notwithstanding the strategies that 
target the eDNA are promising, further research must be developed in order to find more 
widely effective agents [59]. For this purpose it is necessary to bear in mind that the 
importance of the different components of the EPS matrix for the integrity of the biofilm is 
dependent of the growth conditions, medium and substrates [34]. In addition, the use of 
DNase for biofilm removal is effective, but dependent on the age of the biofilm. Probably, once 
the biofilm has aged past a certain point, the role of eDNA in biofilm matrix is supplemented or 
replaced by other matrix components. This, together with the difficult access to eDNA (possibly 
this element is linked to another that protects it from enzymatic degradation performed by 
DNase, i.e. that acts as a shield), calls the question of the efficiency of DNase treatment. In 
this context, it is therefore necessary to consider how eDNA can be reachable to DNase, or 
alternatively how its interactions with other matrix components can be weakened. Finally, 
production of DNase is currently expensive and consequently unacceptable for large-scale use 
[59] due to the glycosylation of this enzyme after translation, which impedes the use of 
inexpensive prokaryotic expression systems [116]. Swapping mammalian DNase to bacterial 
extracellular nucleases in E. coli expression systems could offer a route to lower production 
costs [59,117]. However, the effectiveness and stability of bacterial nucleases in the 
prevention of the biofilm formation should be assured (for example, making use of the yeast 
Pichia pastoris modified) [59]. 
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Alternative strategies to degradation of eDNA by DNase, could be the destabilization of 
the interactions between eDNA and other biomolecules (in the EPS matrix or on the cell 
surface via the proteins that crosslink eDNA strands in the matrix – eDNA has an extensive and 
highly organized network) [59,118] or target components that substitute or supplement the 
role of eDNA in the structural stability of the mature biofilm [119]. Evidently, the first approach 
requires deep knowledge of these interactions, and preferentially the components should be 
common among bacteria (such as polysaccharides and proteins). In this sense, a broad-range 
enzymatic approach to weaken biofilms by enzymatic degradation of the EPS matrix should 
thus ultimately combine the activity of enzymes that target not only eDNA, but also 
polysaccharides and proteins [59]. As mentioned, examples of protein-eDNA interactions are 
the DNA-binding IHF (a member of the DNABII family, vital for biofilm development and 
stability due to its support to the structural network of eDNA [119,120]) and the Beta toxin 
(establishes covalent crosslinks to itself in the presence of DNA, developing the skeletal 
structure upon which staphylococcal biofilms are settled [121]). In addition, targeting the 
control mechanisms for nuclease production in bacteria encourages the production of 
extracellular nucleases and thereby the natural dispersal mechanism of several biofilm-forming 
bacteria [59]. The most vital enzymes in the degradation of the biofilm matrix and release of 
bacterial cells into the surrounding environment are the secreted cysteine proteases 
(staphopains), V8 serine protease (SspA) and Nuc. The relative significance of each enzyme 
will depend on the strain-specific composition of the biofilm matrix. The targets of the main 
proteases (V8, aureolysin (Aur), staphopains) are still not completely described, though some 
candidate surface proteins, like the FnBPs and ClfB, have been identified. Furthermore, the 
function of Nuc in biofilm dispersal has not been scrutinized in detail. The same happens with 
other exo-enzymes also important in dispersal mechanisms, such as hyaluronidase and 
lipases. In addition to the matrix-degrading mechanisms, it is probable that D-amino acids and 
the severe response may play a role in dispersal, but supplementary work is needed to better 
characterize these mechanisms. Accordingly, further work on this topic will permit developing 
better treatment options for biofilm-mediated diseases [85].  
Based on the reported results, it is believed that the presence of DNase I in therapy 
will significantly decrease the initial bacterial adhesion, matrix formation and strong biofilm 
formation permitting the effective killing of remaining bacterial cells with the minimal use of 
antibacterial agents. 
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4.5. XTT assay and cell adhesion assay using U-2 OS cells 
Interaction between the surface of implants and biological tissues is an important 
aspect of biomaterials research [122], determining the success of the materials implantation. 
In this study, two tests to determine the existence of negative effects on mammalian cells 
caused by contact with the developed PLGA coatings were performed. Specifically, XTT was 
used to measure the metabolic activity of the cells, and a cell adhesion assay was performed 
to test the ability of cells to adhere to the various substrata.  
U-2 OS osteoblast-like cells were used because of their ease of growing, although 
cancer cell lines may not represent all aspects of in vivo cell behavior [37].  
 
4.5.1. XTT assay 
The tetrazolium salts, 3-(4,5-dimethyl-2-thiazol)-2,5-di-phenyl-2H-tetrazolium bromide 
(MTT) and XTT are commonly used test methods to measure cell viability and proliferation 
[123]. Despite both methods present equivalent sensitivity, the reduced assay time and 
sample handling (by eliminating the need to solubilize the formazan product prior to 
absorbance measurements) justify the use of XTT instead of MTT [124]. The XTT is based on 
the assumption that shortly after the death of the cell, inactivation of mitochondrial 
dehydrogenases enzymes occurs and that loss of cell viability can be measured using a 
tetrazolium derivative [97]. The amount of water-soluble product generated from XTT (orange 
formazan product) is proportional to the number of metabolically active cells, i.e. the greater 
the number of metabolically active cells in the well, the greater the activity of mitochondrial 
enzymes, and the higher the concentration of the dye formed [96,123,125].  
After 24 h incubation, the metabolic activity of the U2-OS cells was measured not only 
of the cells adhered to the titanium uncoated substrata and each PLGA coating, but also of the 
cells adhered to the surface of the 6-well polystyrene plate in which substrata were incubated. 
The lack of general anti-fouling properties was confirmed by cell attachment and spreading, 
whereas biocompatibility was affirmed by comparing the metabolic activity of cells on coatings 
to uncoated titanium and the surface of the well plate. No significant differences between the 
metabolic activity of the cells attached to the polystyrene surface and the cells adhered to the 
different substrata were observed, indicating that cells were not impeded in their normal 
metabolism on the different substrata(Figure 3.12). 
Discussion 
 84 | Chapter 4 
 
In the analysis of the XTT test results, the uncoated titanium material was taken as a 
reference. The metabolic activity of the cells adhered to these materials and to the well 
surrounding it was taken as 100% metabolic activity. A reference value is needed since the XTT 
assay is a method of comparison. Titanium was considered to be a good reference to compare 
metabolic activity since is a biological inert, non-toxic material and commonly used to 
manufacture various implants (such as hip and knee prosthesis, bone plates, screws and pins 
for fixation, dental implants and artificial spines, and so on) [12,126,127]. Afterwards, all the 
values obtained for the metabolic activity of the U2-OS cells adhered to the various PLGA 
coatings and to the corresponding wells where the incubation was executed have been 
normalized considering a basis of 100%. Accordingly, the values for the metabolic activity are 
all very similar with the ones for titanium, since all of them are around 100%. In addition, there 
are no statistically significant differences among the metabolic activity of the cells adhered to 
the various PLGA coatings and to the respective incubation well, indicating that the viability and 
proliferation of U2-OS cells were analogous in both surfaces, or in other words, the contact of 
the cells with the PLGA coatings do not negatively affect their viability and proliferative capacity 
(Figure 3.12). 
 
4.5.2. Cell adhesion assay  
The biocompatibility of both existing and novel medical devices is a crucial topic to be 
considered in order to determine the hypothetical toxicity resulting from body contact with a 
material or medical device [128]. Apart from good physicochemical and mechanical 
properties, the most critical condition for a biomaterial is its biocompatibility in a certain 
environment, coupled with the non-cytotoxicity of its degradation products [129]. The key 
parameters of the cell-biomaterial interaction are cell adhesion and spreading (topic not 
detailed in this study). It is important to understand which surface properties encourage cell 
adhesion, subsequent spreading and cell growth. Occasionally, surface modification or surface 
coating increases the capability of particular materials to support cell adhesion and/or 
spreading [128].   
Regardless of the route of infection (peri-/early postoperative or late postoperative 
infections), the destiny of a biomaterial implant depends on the outcome of the “race for the 
surface” between efficacious tissue integration of the material implant and biofilm formation.  
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If tissue cells win this competition, then the biomaterial surface is entirely integrated by tissue 
cells and less susceptible to bacterial biofilms. Alternatively, if bacteria win the race, bacterial 
cells will colonize the implant surface and tissue cell functions are impeded by bacterial 
virulence factors and excreted toxins. Unfortunately, since microorganisms are commonly 
introduced on an implant surface during surgery, they have a head start in this race for the 
surface [37,38]. In addition, biomaterial implants are usually not completely integrated with 
host tissue especially when they consist of metal parts that are not easily colonized by host 
tissue cells or, in the case of orthopedic implants, when the repeated hinging can damage the 
surface exposing adhesive sites for bacteria colonization. Hence, the establishment of a robust 
interface with fusion between biomaterial surface and bone tissue is essential, requiring 
adhesion, proliferation and differentiation of tissue cells for successful implantation [37].  
The presented results show complete coverage of all sample materials by U2-OS cells 
after 24 h incubation, indicating a rapid and complete surface coverage of mammalian cells, 
which crucial for the successful integration of the implant within the host tissue [37]. 
Additionally, good coverage of the polystyrene surface of the 6-well plate was observed. This is 
aligned with what expected, since the this material is specifically designed to support the 
adhesion and growth of mammalian cells [130]. U2-OS cells were observed firmly attached 
and spread, elongated in shape, whereas also rounded cells in the process of cell division were 
present. With the exception of few areas on the surface, full coverage by cells was reached in 
all cases (Figure 3.13). There were no significant differences between the number of U2-OS 
cells per cm2 adhered to each substratum and to the respective well, or between the titanium 
and coated surfaces. Based on these results, the coatings do not exhibit toxicity towards these 
cells (Figure 3.14), permitting unhindered tissue integration, which is a requirement for a 
successful result of biomaterial associated surgery in many applications [12].   
The objective of the study discussed in this subchapter was to analyze the existence of 
negative effects in the adhesion of U2-OS cells caused by contact with the diverse coatings. 
More elaborate experiments such as the race for surface between mammalian cells and 
bacterial cells in vitro have not been performed. Nevertheless, studying the behavior of U2-OS 
cells in the presence of S. aureus and perhaps even immune cells (such as macrophages) 
could be interesting to simulate the in vivo conditions, allowing more advanced evaluation of 
the developed coatings prior to animal experiments or human trials, than based on single 
studies of microbial adhesion to or mammalian cells interactions with such coatings [38].   
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In a study developed by Subbiahdoss and co-workers [37], it was demonstrated that 
despite the presence of macrophages, U2-OS cells loose the race for the surface (PMMA) in 
the presence of highly virulent S. aureus or P. aeruginosa, while cells can survive at least 48 h 
in the presence of S. epidermidis, regardless of the absence or presence of macrophages. 
Even with a complete coverage of U2-OS cells on the biomaterials surface after 24 h 
incubation, bacterial cells – in this case S. aureus ATCC 12600GFP and S. aureus Newman 
D2CGFP – can access the surface of the PLGA coating covering the titanium. However, as 
discussed in the section 4.4, it is expected that the presence of DNase I in the PLGA coating 
(at least in both PLGA-DNase I and PLGA-inulin packaged DNase I coatings) will prevent the 
initial bacterial adhesion and, subsequently the biofilm formation, allowing the colonization of 
the surface by tissue cells. 
 
4.6. Pilot experiment: effect of gentamicin when 
combined with the PLGA coatings containing either DNase I 
or inulin-packaged DNase I on the staphylococcal strains 
In this section, the effects of gentamicin sulphate combined with DNase I were 
analyzed on the growth of staphylococcal biofilms. For this purpose, firstly the MIC and MBC 
values of gentamicin for both S. aureus strains were determined and, thereafter biofilms 9 h 
and 24 h old (that growth in the presence of DNase I through exposure to PLGA-DNase I or 
PLGA-inulin packaged DNase I) were exposed to a value between the MIC and the MBC during 
15 h or 24 h, respectively. 
 
4.6.1. Minimum inhibitory concentration and minimum 
bactericidal concentration 
Ideally, the use of antibiotics should be treated as a back-up approach in beginning 
infections and not as a preventive beforehand, the main point is still represented by the sterility 
in the surgical room and by the antiseptic operating procedures [131]. Nonetheless, any 
method which can hypothetically reduce adhesion of bacteria and, consequently, bacterial 
colonization is desired. 
Gentamicin, a polycationic aminoglycoside antibiotic, is a commonly utilized antibiotic 
in orthopedic surgery for local treatment of infection (by means of spacers or beads) [65,132]. 
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For instance, gentamicin is the most frequently used antibiotic for loading bone cement, 
because it can resist to the high temperatures reached during polymerization of the cement 
and also because it is effective against a wide variety of bacteria [133]. This drug can be linked 
to negatively-charged elements (such as residues on the external membrane of Gram-negative 
bacteria and RNA) due to their ionic properties. However, the ionic charges necessary for 
proper functioning of gentamicin may also render it less effective in the presence of bacterial 
biofilms. Alginate and eDNA, both negatively charged, are examples of substances that are 
able to bind and sequester or inhibit gentamicin [65]. The increasing resistance to gentamicin 
of staphylococci in bone infections [134] compels the use of different strategies to battle the 
biofilms. 
The range of values of gentamicin MIC and MBC obtained for both staphylococcal 
strains studied were 4 µg/ml - 8 µg/ml and 8 µg/ml - 16 µg/ml, respectively. To study 
whether antibiotic susceptibility of biofilms increases when combined with DNase I treatment, 
the amount of gentamicin sulphate used was 8 µg/ml, a concentration of drug in-between the 
MIC and the MBC (Table 3.4). In immunosuppressed patients and patients with serious 
infections, immune defense mechanisms are suboptimal. Thus, inhibitory concentration of the 
drug (MIC) may not be sufficient, and obtaining bactericidal concentrations of antimicrobial 
agents at the infection site is essential for accomplishing the treatment. The MBC can be used 
for this purpose [135]. Noteworthy, it is important to emphasize that the dosage of the 
antibiotic differs according to the use for which the medical device is intended and an 
inappropriate dose may be seen as the reason of failure of the prosthesis, as it may originate 
the emergence of resistant bacteria [131]. Clinically, the administered dose is much higher 
than 8 µg/ml of gentamicin to prevent orthopaedic infections. For example, the products 
Palacos G and SmarSet GHV are both FDA approved as antibiotics-laden PMMA bone cement 
and contain 0.85 g gentamicin and 1 g gentamicin, respectively [136]. The results should be 
analysed taking into account this information since hypothetically, it is possible to envisage that 
to higher doses of antibiotics correspond to greater inhibition/elimination of microorganisms. 
However, the purpose of this experiment was to evaluate whether susceptibility increases and 
not completely kills biofilms within the analysed time window. From the results obtained it 
should be possible to extrapolate (for the same clinical scenario) that combining both DNase I 
and gentamicin the outcomes can be as effective as the ones using larger amounts of drug. 
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4.6.2. Biofilm susceptibility to gentamicin 
The anti-adhesive coating analyzed in this thesis exerts its effect by disruption of the 
EPS matrix staphylococcal biofilms, weakening and dispersing biofilms [70]. The bacteria in 
the biofilm (or part of them) are forced to reside in their planktonic state, thereby remaining 
more susceptible to biocide and antibiotic action, as well as eradication by the immune system 
[13]. The combination of DNase I with antibiotics or biocides is an interesting opportunity for 
the development of more effective treatments towards bacterial infections, or development of 
environmentally friendly methods to combat biofilms [59]. In fact, this dispersal-mediated 
treatment will most likely require supplementation with antibiotic therapy responsible for killing 
metabolically active cells and render any remaining persistent cells vulnerable to the immune 
system, as dispersal alone is not sufficient for bacterial removal [85]. 
In most of the experiment, gentamicin sulphate solutions at the MIC (or lower limit of 
MBC, 8 µg/ml) combined with DNase I (present in the PLGA-DNase I and PLGA-inulin 
packaged DNase I coatings) were insufficient to kill staphylococci in their biofilms mode of 
growth (Figure 3.15 – Figure 3.18). Complete inhibition of the biofilms did not occur, which 
could be explained by the fact that MIC values were determined against planktonic organisms, 
neglecting the protective action of the biofilms [132]. However, for a biofilm 24 h old of S. 
aureus ATCC 12600GFP in the presence of PLG-DNase I, there is no practically biofilm on the 
coating surface, i.e. the ratio of biovolume live bacteria/biovolume dead bacteria was virtually 
null (Figure 3.16). The same occurred for a biofilm 48 h old of S. aureus Newman D2CGFP also 
in the presence of PLGA-DNase I coating (Figure 3.18). The coating PLGA-DNase I showed to 
be more efficient in the prevention of biofilm formation than the PLGA-inulin packaged DNase I, 
probably because the last coating has five times less concentration of DNase I – in contrast to 
that observed in section 4.4, the amount of DNase I seems to have a more prominent effect 
when combined with gentamicin. Additionally, it was verified that in the presence of DNase I 
and gentamicin, the ratios of biovolume live bacteria/biovolume dead bacteria for both S. 
aureus strains were considerably lower when compared to the ones on the titanium surface 
uncoated, i.e. only in the presence of gentamicin. Finally, the combination of DNase I with 
gentamicin seems to be less effective for S. aureus ATCC 12600GFP, since this strain presents 
superior ratio of biovolume live bacteria/biovolume dead bacteria in both analyzed time points 
(Figure 3.16 and Figure 3.18). 
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It is important to note that this experiment was only performed one time (hence the SD 
are not present in the Figure 3.16 and Figure 3.18), whereby it should be repeated in the 
future to ensure the reproducibility of the obtained results. 
Even though only a single pilot experiment was performed the preliminary result 
suggests that the combination of gentamicin with DNase I is more efficient in preventing 
biofilm formation for 24 h (Figure 3.10.A) and Figure 3.16). This study was not the first 
combining DNase I and gentamicin. For example, a study developed by Aspe and co-workers 
[65], showed that chemical disruption of an established P. aeruginosa biofilm with DNase or 
AlgL (separately or in combination) increased the susceptibility of the culture to gentamicin. 
Increased antibiotic susceptibility has also been observed with other dispersal agents such as 
dispersin B and proteinase K [85].  
Although promising, the combination of antibiotic therapy with a dispersal agent (or, in 
particular, gentamicin coupled with DNase I) presents serious concerns with regards to the 
induced dispersal, which could result in acute infections if the antibiotic does not succeed on 
the eradication of the released cells (potentially leading to systemic infection). Additionally, 
embolism formation resulting from the release of cell clumps embedded in matrix components 
(generation of large detached biofilm chunks that have intrinsic resistance characteristics) 
could be a risk of dispersal treatments [75,85]. Sub-inhibitory concentrations of β-lactams 
have also been related to the induction of eDNA release and biofilm formation, which is 
counter-productive when coupled with a dispersal agent. Further studies are needed to address 
these challenges before dispersal agents are tested in a clinical setting [85].  
Alternative to the technique used, antibiotics may be directly included in the 
biodegradable PLGA coating [12] and/or could be combined with a second antibiotic. 
Occurrence of gentamicin-resistant bacterial strains in prosthesis-related infections (nearly 50% 
of the staphylococci) has led to the development of antibiotic-loaded bone cements in which 
gentamicin is combined with a second antibiotic [133]. The most commonly mixed antibiotics 
are gentamicin and tobramycin (also an aminoglycoside) and vancomycin (a glycopeptide 
active mainly on gram-positive like, e.g., S. aureus) [131]. Therefore, a combination of 
antibiotics may reduce the occurrence of antibiotic resistance [133] and possibly increase the 
efficiency of the developed method preventing the biofilm formation. 
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5.1. Concluding remarks 
In the present work, the effect of a protective, biodegradable PLGA coating containing 
DNase I or inulin-packaged DNase I on bacterial adhesion and biofilm formation of two S. 
aureus strains was studied. 
Coating the surfaces of the implants is one of the techniques that must be explored to 
prevent the adhesion of bacteria and consequent formation of biofilms. Different particles 
(inulin, DNase I or inulin-packaged DNase I) were obtained by spray-drying, with a very similar 
size, and were separately incorporated in PLGA, generating titanium coatings with smooth 
surfaces, reduced thickness and different degradation rates in PBS. Coatings without DNase I 
particles – PLGA and PLGA-inulin – presented shorter times of degradation than those with – 
PLGA-DNase I, PLGA-DNase I (1/5) and PLGA-inulin packaged DNase I (presented the longest 
degradation period). Regarding the release of DNase I particles for both PLGA-DNase I and 
PLGA-inulin packaged DNase I coatings, an initial burst of drug release (partially explained for 
the reduced thickness) occurred, followed by a longer period of gradual release. In order to 
optimize the efficiency of these coatings, the initial burst release was efficiently avoided placing 
an extra layer of PLGA on the top of the active layer, since it was prevented the contact 
between the active substances in the coatings and the surrounding environment, PBS. 
In accordance with previous studies, it was demonstrated that eDNA is required for 
biofilm development, since the coating of titanium with PLGA incorporating DNase I particles 
(regardless of whether particles consisted of only DNase I or inulin-packaged DNase I) 
drastically decreases the initial bacterial adhesion in vitro. Additionally, the coatings PLGA-
DNase I and PLGA-inulin packaged DNase I significantly reduced the biofilm formation on 
titanium surfaces in vitro for 24 h, 72 h and 120 h of biofilm growth for both staphylococcal 
strains. After comparing the results achieved for the coatings with the same concentration of 
DNase I, it is also possible to conclude that by packaging DNase I in inulin, DNase I underwent 
less damage during the coating process. Regarding the biocompatibility, none of the PLGA 
coatings tested adversely affected the capability of tissue cells to proliferate and to adhere, 
presenting a similar proliferation capacity and adherence to that which occurs in the uncoated 
titanium surfaces. Finally, the combination of DNase I (present in the PLGA-DNase I and PLGA-
inulin packaged DNase I coatings) with a small amount of gentamicin (8 µg/ml) increased the 
bactericidal susceptibility, resulting in low biovolumes for biofilms 24 h and 48 h old. 
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5.2. Future perspectives 
From the results obtained in this work, a number of suggestions can be proposed for 
future studies:  
i. The presented method of protecting and packaging can be applied using other 
enzymes (such as lysozyme and dispersin B) that are known to be able to 
prevent bacterial adhesion and biofilm formation [12]. 
 
ii. Explore further opportunities for destabilizing the intermolecular interactions in 
the biofilm matrix, leaving it more susceptible to physical and chemical 
stresses. In addition, targets of V8, Aur, staphopains; and, also, the function of 
Nuc and D-amino acids in biofilm dispersal should be identified [85]. 
 
iii. The benefits of an extra PLGA layer on the top of the active PLGA coating that 
avoids the initial burst release of DNase I should be considered. 
 
iv. The kinetics release of DNase I and inulin provided in this thesis was based on 
the assumption that these substances within the PLGA layer did not suffered 
degradation, i.e. only the DNase I and inulin particles released from the 
protective PLGA coating undergo degradation. In this regard, to obtain a more 
complete picture of what really happens with these substances inside of the 
polymeric layer, the activity (or loss of it) of the DNase I and inulin should be 
examined. This information would help to determine the amount of DNase I 
that should be included per particle of inulin in the PLGA-inulin coating with 
incorporated DNase I, for instance.  
 
v. Implement an in vitro model based on the herein performed pilot experiment 
to determine whether the anti-biofilm treatment based on the protective PLGA 
coating incorporating DNase I particles increases the susceptibility to different 
antibiotics (such as gentamicin vancomycin, rifampicin, tobramycin) currently 
used clinically to prevent and/or treat infections.  
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vi. Test the efficiency of the PLGA-DNase I and PLGA-inulin packaged DNase I 
coatings with different species of bacteria, since the work provided in this 
thesis was limited to two staphylococcal strains presenting fluorescence due to 
limitations of available equipment. 
 
vii. Finally, perform in vivo (animal) experiments applying the approach developed 
in this thesis. Notwithstanding the diversity possible in in vitro models currently 
available to identify or test anti-biofilm molecules, these models only partially 
reflect in vivo situations and for now it remains impossible to mimic the 
complexity of interactions between bacteria and the immune system in vitro 
[74]. 
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Appendix A – Particles dimension 
The size distribution of inulin (Figure A.1), DNase I (Figure A.2) and inulin-packaged 
DNase I (ratio 4:1) (Figure A.3) particles was determined by laser diffraction. 
 
 
Figure A.1. Size distribution (µm) of inulin particles. 
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Figure A.2. Size distribution (µm) of DNase I particles. 
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Figure A.3. Size distribution (µm) of inulin-packaged DNase I (ratio 4:1) particles. 
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Appendix B – DNase I and inulin calibration curves  
Calibration curves were performed for further DNase I and inulin quantification. 
Calibration curves of DNase I (Figure B.1) and of inulin (Figure B.2) reflect the relationship 
between the concentration (µg/ml) of these substances and optical density (595 nm or 630 
nm, correspondingly). 
 
 
Figure B.1. Calibration curve of DNase I (595 nm) solution as a function of their concentration in solution 
(µg/ml) obtained spectrophotometrically. Error bars indicate SD over three experiments with separately 
prepared DNase I solutions. 
 
 
Figure B.2. Calibration curve of inulin (630 nm) solution as a function of their concentration in solution 
(µg/ml) obtained spectrophotometrically. Error bars indicate SD over three experiments with separately 
prepared inulin solutions. 
